Document:

Amended and Restated Employment Agreement dated December 4, 2003

 EXHIBIT 10.5 
  
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
  
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) dated as of December 4, 2003 by and among NPTest
Acquisition Corporation, a Delaware corporation (together with its successors, the “Company”), NPTest Holding Corporation, a Delaware corporation (together with its successors, “Parent”), and Jean-Luc Pelissier
(“Executive”), effective as the date hereof. 
  
 WHEREAS, Executive entered into an Employment Agreement with the Company and Parent dated as of July 29, 2003 (the “Original Employment Agreement”), pursuant to which Executive agreed to continue his employment with the
Company after the closing of transactions contemplated by the Stock Purchase Agreement dated as of June 24, 2003 (the “Stock Purchase Agreement”), among Parent, the Company, and Schlumberger Technology Corporation, Schlumberger
Technologies, Inc., and Schlumberger B.V.; 
  
 WHEREAS, each of
the Company and Parent considers it in its best interests and the best interests of its stockholders to foster the continued employment of Executive from and after the date hereof; 
  
 WHEREAS, Executive is willing to continue his employment on and after the date hereof on the terms hereinafter set forth in
this Agreement; 
  
 NOW THEREFORE, in consideration of the
foregoing and of the mutual covenants and agreements of the parties set forth in this Agreement, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally
bound, agree to amend and restate the Original Employment Agreement in its entirety as follows: 
  
 ARTICLE 1 
 POSITION; TERM OF AGREEMENT

  
 Section 1.01. Position. (a) As of and following the
Effective Date, Executive shall serve as President—Products and shall report to the Chief Executive Officer. Executive shall have such duties and authority, consistent with such position, as shall be determined from time to time by the Chief
Executive Officer. 
  
 (b) During the Employment Term, Executive
will devote substantially all of his business time to the performance of his duties under this Agreement and will not engage in any other business, profession or occupation for compensation or otherwise which would conflict with the rendition of
such services either directly or indirectly, without the prior written consent of the Board. 

 Section 1.02. Term. Executive shall be employed by the Company for a period (the
“Employment Term”) commencing on the Effective Date and, subject to earlier termination or extension as provided herein, ending on the second anniversary of the Effective Date; provided that on each anniversary of the
Effective Date beginning on such second anniversary, the Employment Term shall be automatically extended for successive one-year periods unless not later than one month prior to any such automatic extension the Company or Executive shall give notice
that the Employment Term shall not be extended. 
  
 ARTICLE 2

 COMPENSATION AND BENEFITS 
  
 Section 2.01. Base Salary. Commencing on the date hereof, the Company shall pay Executive an annual base salary (the
“Base Salary”) at the initial annual rate of $300,000 payable in accordance with the payroll and personnel practices of the Company from time to time. 
  
 Section 2.02. Performance Bonus. (a) Subject to Executive’s continued employment hereunder through December 31,
2003, Executive will be eligible to receive a bonus with a target bonus opportunity up to 75% of the pro-rated portion of Base Salary for the period from the Effective Date through December 31, 2003, based on attainment of such goals as the Board
shall determine. For each calendar year thereafter, subject to Executive’s continued employment hereunder on December 31 of such year, Executive shall be eligible for an annual bonus (the “Annual Bonus”), with a target bonus
opportunity of up to 75% of Base Salary, based on attainment of such goals as the Board shall determine each year. The Annual Bonus for each calendar year (including the bonus for the period ending December 31, 2003) shall be paid in a lump sum
payment on or before March 31 of the following calendar year. In the event that following a Change in Control, (i) Executive is terminated without Cause or (ii) Executive terminates his employment due to a material diminution in authority as
compared to the authority of his title or position immediately prior to the Change in Control, and in the case of either clause (i) or (ii) such termination occurs during the fiscal year in which the Change in Control becomes effective, then
Executive will be entitled to receive a pro rata portion of Executive’s Annual Bonus for the year in which such termination occurs based on the number of weeks Executive has been employed by the Company during such year as of the Change in
Control. 
  
 (b) For the portion of the 2003 calendar year prior
to the Effective Date, Executive shall be eligible for a bonus based on the performance goals for 2003 previously determined by the US Company and Schlumberger and provided to the Company. 
  
 Section 2.03. Employee Benefits. During the Employment Term, Executive
shall be eligible for employee benefits (including fringe benefits, vacation and health, accident and disability insurance, and retirement plan 
  

 2 

 participation) substantially similar to those benefits made available generally to senior executives of the Company.

  
 Section 2.04. Business And Travel Expenses. Reasonable
travel, entertainment and other business expenses incurred by Executive in the performance of Executive’s duties hereunder shall be reimbursed by the Company in accordance with Company policies as in effect from time to time. 
  
 Section 2.05. Options. (a) On or promptly after the Effective Date,
the Company shall grant to Executive an option (the “Option”) to purchase 1,250,000 shares of common stock of Parent (“Common Stock”), at an exercise price per share equal to the fair market value (determined in
accordance with the terms of the Plan) of a share of Common Stock on the grant date. 
  
 (b) Subject to Executive’s continued employment with the Company or one of its Affiliates as of the applicable vesting date, (i) 25% of the shares constituting the Option shall become vested and exercisable on
the first anniversary of the Effective Date, and (ii) thereafter, the Option shall become vested and exercisable at a rate of  1/48 of the shares constituting the Option per month. 
  
 (c) Upon termination of Executive’s employment by the Company without Cause or by Executive for Good Reason within 12 months after a Change in Control, any unvested portion of the Option shall become vested and
exercisable to the extent the Option would have otherwise become vested and exercisable during the 18 months following the date of such termination. 
  
 (d) Except as set forth herein, the Options shall otherwise be subject to the terms of the Parent Stock Incentive Plan (the “Plan”), a
copy of which is attached hereto as Attachment 1. 
  
 (e) Upon
termination of Executive’s employment, subject to Section 3.02 hereof, the Company shall have the right to repurchase the shares of Common Stock acquired upon exercise of the Option in accordance with the terms of the Plan and the applicable
award agreement. 
  
 ARTICLE 3 
 CERTAIN TERMINATION BENEFITS 
  
 Section 3.01. Certain Events. (a) A “Qualifying Event” means the termination of Executive’s
employment by the Company without Cause (other than by reason of Executive’s death or disability). 
  
 (b) Each party hereto shall give to the other party 30 days prior written notice of such party’s intent to terminate Executive’s employment with
the Company for any reason. 
  

 3 

 (c) The receipt of any payments and benefits pursuant to this Article 3 by Executive shall be contingent
upon Executive signing a release of claims arising from Executive’s employment and the termination thereof in a form reasonably acceptable to the Company. 
  

Section 3.02. Benefits Upon A Qualifying Event. In the event of a Qualifying Event during the Employment Term, Executive shall be entitled to
the following benefits: 
  
 (a) The Company shall
pay Executive as soon as practicable a lump sum, in cash, equal to one times the annual Base Salary in effect as of the date hereof. 
  
 (b) On the first anniversary of the Qualifying Event and subject to Executive’s compliance with the covenants set forth in Section
4.01 hereof, the Company shall pay Executive a lump sum, in cash, equal to 0.5 times the annual Base Salary in effect as of the date hereof. 
  
 Section 3.03. Separation Benefits. In the event of any termination of employment during the Employment Term (including a Qualifying Event),
Executive (or his estate, as the case may be) shall be entitled to the benefits set forth below: 
  
 (a) The Company shall pay Executive as soon as practicable a lump sum, in cash, equal to Executive’s earned but unpaid Base Salary
for the period through and including the date of termination of Executive’s employment (collectively, “Accrued Compensation”). In addition, Executive shall be entitled to any other vested benefits earned by Executive for the
period through and including the date of termination of Executive’s employment under any other employee benefit plans and arrangements maintained by the Company, in accordance with the terms of such plans and arrangements, except as modified
herein (collectively, “Accrued Benefits”). 
  
 ARTICLE 4 
 COVENANTS AND REPRESENTATIONS 
  
 Section 4.01. Nondisclosure, Noncompetition, Nonsolicitation, and
Nondisparagement. (a) Executive shall not (except to the extent required by an order of a court having competent jurisdiction or under subpoena from an appropriate government agency) disclose to any third person, whether during or subsequent to
the Executive’s employment with the Company, any trade secrets; customer lists; provider lists; product development and related information; marketing plans and related information; sales plans and related information; premium or any other
pricing information; operating policies and manuals; research; payment rates; methodologies; contractual forms; business plans; 
  

 4 

 financial records; or other financial, commercial, business or technical information related to the Company or any
Affiliate of the Company unless such information has been previously disclosed to the public by the Company or has become public knowledge other than by a breach of this Agreement; provided that this limitation shall not apply to any such
disclosure made while the Executive is employed by the Company or its Affiliate if such disclosure occurred in connection with the performance of Executive’s job as an employee of the Company or its Affiliates. Executive agrees that upon
termination of Executive’s employment with the Company for any reason, Executive will return to the Company immediately all memoranda, books, papers, plans, information, letters and other data, and all copies thereof or therefrom, in any way
relating to the business of the Company or its Affiliates. Executive further agrees that Executive will not retain or use for Executive’s account at any time any trade names, trademark or other proprietary business designation used or owned in
connection with the business of the Company or its Affiliates. 
  
 (b) While employed by the Company, Executive shall not, on his account, or as an employee, consultant, independent contractor, partner, owner, officer, director or stockholder, engage in, be connected with, have any interest in, or aid or
assist anyone else to engage in, be connected with, or have any interest in, any firm or person which directly competes with a line or lines of business which the Company or Parent (or any of their Subsidiaries) was engaged in or sought to be
engaged in during the Employment Term; provided that Executive may purchase securities in any corporation whose securities are listed or traded on a national securities exchange or in an over-the-counter securities market if such purchases do
not result in Executive beneficially owning, directly or indirectly, at any time 5% or more of the equity securities of any such corporation. 
  
 (c) While employed by the Company and for 18 months after the termination of Executive’s employment, Executive shall not, directly or indirectly:

  
 (i) induce or attempt to induce any employee
of Parent or the Company (or any Subsidiary of Parent or the Company) to be employed or perform services elsewhere; 
  
 (ii) solicit or attempt to solicit the trade of any individual or entity which, at the time of such solicitation, is a customer of Parent
or the Company (or any Subsidiary of Parent or the Company) or which Parent or the Company (or any Subsidiary of Parent or the Company) is undertaking reasonable steps to procure as a customer at the time of or immediately preceding termination of
employment; provided, however, that this limitation shall only apply to any product or service which is in competition with a product or service of Parent or the Company (or any Subsidiary of Parent or the Company). 
  

 5 

 (d) In connection with the termination of Executive’s employment hereunder, Executive shall
cooperate with the Company and any Affiliate of the Company to ensure an orderly transition, in such a manner and at such times as the Company shall reasonably request. 
  
 (e) Except as required by law, neither party will at any time (whether during or after termination of Executive’s
employment with the Company) knowingly make any statement, written or oral, or take any other action that would disparage or otherwise harm the other party, its business or reputation or, in the case of the Company, the reputation of any of its
Affiliates or the officers and directors of any of them. 
  
 Section 4.02. Material Inducement; Specific Performance. (a) If any provision of Section 4.01 is determined by a court of competent jurisdiction not to be enforceable in the manner set forth in this Agreement, the Company and
Executive agree that it is the intention of the parties that such provision should be enforceable to the maximum extent possible under applicable law and that such court shall reform such provision to make it enforceable in accordance with the
intent of the parties. 
  
 (b) Executive acknowledges that a
material part of the inducement for the Company to provide the compensation provided herein is Executive’s covenants set forth in Section 4.01 and that the covenants and obligations of Executive with respect to noncompetition, nondisclosure and
nonsolicitation relate to special, unique and extraordinary matters and that a violation of any of the terms of such covenants and obligations will cause the Company irreparable injury for which adequate remedies are not available at law. Therefore,
Executive agrees that, if Executive shall materially breach any of those covenants during or following termination of employment, the Company shall be entitled to an injunction, restraining order or such other equitable relief (without the
requirement to post a bond) restraining Executive from committing any violation of the covenants and obligations contained in Section 4.01 and the Company shall have no further obligation to pay Executive any benefits otherwise payable hereunder.
The remedies in the preceding sentence are cumulative and are in addition to any other rights and remedies the Company may have at law or in equity as an arbitrator (or court) shall reasonably determine. 
  
 Section 4.03. Employee Representation. Executive expressly represents
and warrants to the Company that Executive is not a party to any contract or agreement and is not otherwise obligated in any way, and is not subject to any rules or regulations, whether governmentally imposed or otherwise, which will or may restrict
in any way Executive’s ability to fully perform Executive’s duties and responsibilities under this Agreement. 
  

 6 

 ARTICLE 5 
 SUCCESSORS AND ASSIGNMENTS 
  
 Section 5.01. Assignments. Except for an assignment in the event of a Change in Control or an assignment to an Affiliate of the Company, this
Agreement shall not be assignable by the Company without the written consent of Executive. This Agreement shall not be assignable by Executive. 
  
 Section 5.02. Successors; Binding Agreement. This Agreement shall inure to the benefit of and be binding upon personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees, and legatees. 
  
 ARTICLE 6 
 MISCELLANEOUS 
  
 Section 6.01. Notices. Any notice required to be delivered hereunder shall be in writing and shall be addressed:

  

	 	(i)	 	if to the Company, to: 

  
 c/o NPTest, Inc. 
 150 Baytech Drive

 San Jose, CA 95134 
 Attention:
Chief Executive Officer 
 Fax: (408) 586-4661 
  
 with copies to: 
  
 Davis Polk & Wardwell 
 1600 El Camino
Real 
 Menlo Park, CA 94025 
 Tel: 650-752-2000 
 Fax: 650-752-2111 
 Attn: David W. Ferguson 
  

	 	(ii)	 	if to Executive, to Executive’s last known address as reflected on the books and records of the Company; 

  
 or, in each case, to such other address as such party may hereafter specify for the purpose
by written notice to the other party hereto. Any such notice shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in the place of receipt and such day is a business day in the place of receipt.
Otherwise, any such notice shall be deemed not to have been received until the next succeeding business day in the place of receipt. 
  

 7 

 Section 6.02. Dispute Resolution. (a) Except as provided in Section 4.02, each of Executive and
the Company shall have the right and option to elect (in lieu of litigation) to have any dispute or controversy arising under or in connection with this Agreement settled by arbitration in a location in California, in accordance with the rules of
the American Arbitration Association then in effect. Executive’s election to arbitrate, as herein provided, and the decision of the arbitrator in that proceeding, shall be binding on the Company and Executive. Judgment may be entered on the
award of the arbitrator in any court having jurisdiction. 
  
 (b)
Each party shall pay its own expenses of such arbitration or litigation and all common expenses of such arbitration or litigation shall be borne equally by Executive and the Company. Each party to an arbitration or litigation hereunder shall be
responsible for the payment of its own attorneys’ fees. 
  
 Section 6.03. Unfunded Agreement. The obligations of the Company under this Agreement represent an unsecured, unfunded promise to pay benefits to Executive and/or Executive’s beneficiaries, and shall not entitle Executive or
such beneficiaries to a preferential claim to any asset of the Company. 
  
 Section 6.04. Non-exclusivity Of Benefits. Unless specifically provided herein, neither the provisions of this Agreement nor the benefits provided hereunder shall reduce any amounts otherwise payable, or in any way diminish
Executive’s rights as an employee of the Company, whether existing now or hereafter, under any compensation and/or benefit plans (qualified or nonqualified), programs, policies, or practices provided by the Company, for which Executive may
qualify; provided, however, that the Severance Benefits shall be in lieu of any severance benefits under any such plans, programs, policies or practices. Vested benefits or other amounts which Executive is otherwise entitled to receive
under any plan, policy, practice, or program of the Company (i.e., including, but not limited to, vested benefits under any qualified or nonqualified retirement plan), at or subsequent to the date of termination of Executive’s employment shall
be payable in accordance with such plan, policy, practice, or program except as expressly modified by this Agreement. 
  
 Section 6.05. Employment Status. Nothing herein contained shall interfere with the Company’s right to terminate Executive’s employment
with the Company at any time, with or without Cause, subject to the Company’s obligation to provide benefits pursuant to Article 3, if any. Executive shall also have the right to terminate Executive’s employment with the Company at any
time without liability, subject only to the provisions hereof and Executive’s obligations hereunder. 
  
 Section 6.06. Entire Agreement. This Agreement represents the entire agreement between Executive and the Company and its Affiliates with respect to
Executive’s employment and/or severance rights, and supersedes all prior discussions, negotiations, and agreements concerning such rights; provided, 
  

 8 

 however, that any amounts payable to Executive hereunder shall be reduced by any amounts paid to Executive as
required by any applicable law in connection with any termination of Executive’s employment. 
  
 Section 6.07. Tax Withholding. Notwithstanding anything in this Agreement to the contrary, the Company shall withhold from any amounts payable
under this Agreement all federal, state, city, or other taxes as are legally required to be withheld. 
  
 Section 6.08. Waiver Of Rights. The waiver by either party of a breach of any provision of this Agreement shall not operate or be construed as a
continuing waiver or as a consent to or waiver of any subsequent breach hereof. 
  
 Section 6.09. Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of this Agreement, and
this Agreement shall be construed and enforced as if the illegal or invalid provision had not been included. 
  
 Section 6.10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California without
reference to principles of conflict of laws. 
  
 Section 6.11.
Counterparts. This Agreement may be signed in several counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were on the same instrument. 
  
 ARTICLE 7 
 DEFINITIONS 
  
 For purposes of this Agreement, the following terms shall have the meanings set forth below. 
  
 “Accrued Benefits” has the meaning accorded such term in Section 3.03. 
  
 “Accrued Compensation” has the meaning accorded such term in Section 3.03. 
  
 “Affiliate” has the meaning accorded to such term in Rule
12b-2 under the Exchange Act. 
  
 “Agreement” has
the meaning accorded such term in the introductory paragraph of this Agreement. 
  
 “Base Salary” has the meaning accorded such term in Section 2.01. 
  

 9 

 “Beneficial Ownership” A Person shall be deemed the “Beneficial Owner” of, and
shall be deemed to “beneficially own,” securities pursuant to Rule 13d-3 under the Exchange Act. 
  
 “Board” shall mean the Board of Directors of the Company. 
  
 “Cause” means the occurrence of any one or more of the following: 
  
 (i) Executive’s willful and continued failure
substantially to perform the duties of Executive’s position as then in effect (other than as a result of incapacity due to physical or mental illness) which failure is not remedied within 15 business days of written notice from the Company;

  
 (ii) Executive’s gross negligence or
willful malfeasance in the performance of Executive’s duties hereunder as then in effect; 
  
 (iii) Executive’s breach of any of the covenants contained in Section 4.01; or 
  
 (iv) Executive’s commission of an act constituting
fraud, embezzlement, or any other act constituting a felony. 
  
 For purposes of
this definition, no act or failure to act shall be deemed “willful” unless effected by Executive not in good faith and without reasonable belief that such action or failure to act was in the best interests of the Company. 
  
 “Change in Control” means the occurrence of any of the
following: 
  
 (i) the consummation of a merger
or consolidation of the Company or Parent with or into any other entity pursuant to which the direct or indirect stockholders of the Company or Parent, as applicable, immediately prior to such merger or consolidation hold less than 40% of the voting
power of the surviving entity; 
  
 (ii) the sale
or other disposition of all or substantially all of the Company’s or Parent’s assets; or 
  
 (iii) any acquisition by any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Exchange
Act and other than the direct and indirect stockholders of the Company immediately after the Effective Date) of the Beneficial Ownership of 60% or more of the voting power of the Company’s or Parent’s equity securities in a single
transaction or series of related transactions, other than in an underwritten public offering of the securities of the Company or its Affiliates; 
  
 provided that a transaction shall not constitute a “Change in Control” if its sole purpose is to change the state of the Company’s or Parent’s
incorporation or to create a holding company that will be owned in substantially the same proportions 
  

 10 

 by the persons who, directly or indirectly, held the securities of the Company or Parent, as applicable, immediately
before such transaction. 
  
 “Code” means the
Internal Revenue Code of 1986, as amended. 
  
 “Effective
Date” means the closing date of the transactions under the Stock Purchase Agreement. 
  
 “Employment Term” has the meaning accorded such term in Section 1.02. 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  
 “Good Reason” means the occurrence of any of the following without Executive’s written consent:

  
 (i) Any change in Executive’s title or
position that constitutes a material diminution in authority as compared to the authority of his title or position as of the Effective Date, or any substantial diminution in Executive’s duties and responsibilities (other than a change due to
Executive’s disability); 
  
 (ii) Any
refusal or failure by the Company to pay compensation or provide benefits in accordance with this Agreement; or 
  
 (iii) Any relocation of Executive’s office or the Company’s principal executive office to a location more than 50 miles from its
location on the Effective Date; 
  
 provided, however, that no act
or failure to act by the Company shall give rise to “Good Reason” if cured within 30 days of written notice by Executive to the Company. 
  
 “Option” has the meaning accorded such term in Section 2.05. 
  
 “Person” means an individual, corporation, partnership, association, trust or any other entity or
organization. 
  
 “Qualifying Event” has the
meaning accorded such term in Section 3.01. 
  
 “Securities Act” means the Securities Act of 1933, as amended. 
  
 “Subsidiary” of any Person means any other Person of which securities or other ownership interests having voting power to elect a majority of the board of directors or other Persons performing similar
functions are at the time directly or indirectly owned by such Person. 
  

 11 

 IN WITNESS WHEREOF, the Company, Parent and Executive have executed this Agreement, to be effective as of
the day and year first written above. 
  

	NPTEST ACQUISITION CORPORATION
		
	 By:
	 	

	 Name:
	 	 
	 Title:
	 	 

  

	NPTEST HOLDING CORPORATION
		
	 By:
	 	

	 Name:
	 	 
	 Title:
	 	 

  

		
	 EXECUTIVE:
	 	 
	
	

	 Name:
	 	 

  

 12Amended and Restated License and Collaboration Agreement

 Exhibit 4.7 
  

AMENDED AND RESTATED 
 LICENSE AND
COLLABORATION AGREEMENT1 
  
 THIS AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), dated as of September 19,
2003, is made between Genzyme Corporation, a Massachusetts corporation having its principal place of business at One Kendall Square, Cambridge, Massachusetts 02139, U.S.A. (“Genzyme”) and Optein Inc., d/b/a Aptein Inc.
(“Aptein”), a Delaware corporation and an Affiliate (as defined herein) of Cambridge Antibody Technology Limited (“CAT”), a company organized under the laws of England and Wales having its principal place of
business at The Milstein Building, Granta Park, Cambridge CB1 6GH, England. Genzyme and Aptein are sometimes referred to herein individually as a “Party” and together as the “Parties.” 
  
 R E C I T A L S 
  
 A. Genzyme and Aptein are parties to a License and Collaboration Agreement effective as of September 27, 2000 (the
“Initial Agreement”) pursuant to which the Parties agreed, inter alia, to develop and commercialize the Collaboration Products (as defined herein) throughout the Territory (as defined herein). 
  
 B. The Parties desire to amend and restate the Initial Agreement to modify
its termination provisions, alter the Parties’ respective obligations to fund Program Costs (as defined herein), establish a committee to facilitate the pursuit of additional applications of Collaboration Products, and update the formula by
which the Parties’ respective Percentage Interests (as defined herein) are calculated. 
  
 NOW THEREFORE, in consideration of the premises and of the covenants herein contained, the Parties mutually agree as follows: 
  
 ARTICLE 1. DEFINITIONS 
  
 For purposes of this Agreement, the terms defined in this Article shall have the meanings specified below. Certain other capitalized terms are defined
elsewhere in this Agreement. 
  
 1.1. “Affiliate”
shall mean any corporation or other entity which controls, is controlled by, or is under common control with a Party. A corporation or other entity shall be regarded as in control of another corporation or entity if it owns or directly or indirectly
controls fifty percent (50%) or more of the voting stock or other ownership interest of the other corporation or entity, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the
corporation or other entity or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the corporation or other entity. 

	1	[***] indicates that text has been deleted which is the subject of a confidential treatment request. This text has been filed separately with the SEC.

 1.2. “Antibody” shall mean a molecule or a gene encoding such a molecule which
specifically binds to one or more isoforms of TGF-ß and which comprises or contains one or more immunoglobulin variable domains or functional parts of such domains, or any existing or future fragments, variants, modifications or derivatives
thereof, provided that such fragments, variants, modifications or derivatives retain at least a functional portion of an immunoglobulin variable domain. 
  

1.3. “BLA” shall mean a Biologics License Application or similar application filed with the FDA after completion of human clinical
trials to obtain marketing approval for a Collaboration Product or an External Product, as the case may be. 
  
 1.4. “Burnham” shall mean The Burnham Institute and any successor body thereto. 
  
 1.5. “Burnham License” shall mean the agreement effective as
of September 1, 2000 among CAT, Burnham and Integra relating to the CAT Patent Rights, the CAT Technology and the Genzyme Patent Rights. 
  
 1.6. “Business and Commercialization Committee” shall mean the joint team composed of representatives of Aptein or its Affiliates and
Genzyme described in Section 8.2.1 hereof. 
  
 1.7. “CAT
Background Patent Rights” shall mean the Patent Rights corresponding to the patents and patent applications listed in Schedule 1.7 hereto. 
  
 1.8. “CAT Patent Rights” shall mean all Patent Rights owned or controlled by, or licensed (with the right to sublicense) to, Aptein and
its Affiliates during the term of this Agreement (other than the CAT Background Patent Rights and the CAT Program Patent Rights), but only to the extent that such Patent Rights claim Collaboration Products or relate to the research, development,
manufacture or commercialization of TGF-ß antagonists. The CAT Patent Rights existing as of the Effective Date are listed in Schedule 1.8 hereto. The Parties acknowledge and agree that the Whittier Patent shall be included in the CAT
Patent Rights for all purposes except for Sections 4.6.1 and 4.6.2 below, in which cases the Whittier Patent shall be expressly excluded from the meaning of CAT Patent Rights. 
  
 1.9. “CAT Product” shall have the meaning ascribed to it in Section 3.5 hereof. 
  
 1.10. “CAT Program Patent Rights” shall mean the Patent
Rights that claim CAT Inventions (as such term is defined in Section 9.1.1 hereof). 
  
 1.11. “CAT Program Technology” shall mean Technology discovered, made or conceived solely by employees of, or others acting on behalf of, Aptein and its Affiliates during and in connection with the
Program. 
  
 1.12. “CAT Technology” shall mean
Technology owned or controlled by, or licensed (with the right to sublicense) to Aptein and its Affiliates during the term of this Agreement (other than the CAT Program Technology), but only to the extent that such Technology relates to the
research, development, manufacture or commercialization of Collaboration Products for use in the Field. 
  

 2 

 1.13. “Collaboration Product” shall mean any Antibody-based antagonist of TGF-ß
that is developed or acquired by either Party or its Affiliates for use in the Field, and any and all improvements, combination products, delivery systems and dosage forms related thereto. 
  
 1.14. “Combination Product” shall mean a product that
contains a Royalty-Bearing Product (as defined in Section 1.44 below) as one component and at least one other functional (whether it be biological or mechanical) component. 
  
 1.15. “Commercialization Costs” with respect to a Collaboration Product shall mean the variable costs and
fixed costs properly incurred by the Parties with respect to work performed by the Parties and their Affiliates and subcontractors in connection with the performance of the Commercialization Plan for such Collaboration Product, including without
limitation (a) the Fully Absorbed Cost of Goods incurred in connection with the production of Collaboration Products in bulk active ingredient and in finished dosage form, including without limitation the performance of assay and purification work,
for use in connection with the performance of the Commercialization Plan, (b) sales and marketing costs related to performing market research, advertising, producing promotional literature, sponsoring seminars and symposia, training, originating
sales, providing reimbursement and other patient support services, and (c) ordinary marketing and distribution expenses, including without limitation recruitment costs and salaries and associated expenses for sales and marketing personnel and
support staff, advertising and promotion costs, transportation expenses, including insurance (but only to the extent not charged to customers and only such proportion of all such costs directly attributable to support of the Commercialization Plan),
irrecoverable duties and taxes, bad debt expense, and costs associated with cash and other trade discounts and allowances and other marketing concessions to customers actually allowed and taken. For the avoidance of doubt, Commercialization Costs
shall exclude any transfer pricing adjustments or taxes payable by a Party to one of its Affiliates in connection with such Affiliates’ performance of activities under a Commercialization Plan. For purposes of this Section 1.15,
“variable costs” shall be deemed to be the cost of labor, raw materials, supplies and other resources directly consumed in the conduct of the Commercialization Plan and manufacture of Collaboration Product for use in
commercialization activities, as well as royalties payable to Third Parties (with such royalty obligations in existence as of the Effective Date being set forth in Schedule 1.15), to the extent not included in Development Costs or Fully
Absorbed Cost of Goods. For purposes of this Section 1.15, “fixed costs” shall be deemed to be the cost of facilities, utilities, insurance, facility and equipment depreciation and other fixed costs directly related to the conduct
of the Commercialization Plan and the manufacture of Collaboration Product for use in commercialization activities, allocated based upon the proportion of such costs directly attributable to support of the Commercialization Plan and the manufacture
of Collaboration Product for use in commercialization activities or by such other method of cost allocation as may be approved by the Steering Committee. All cost determinations made hereunder shall be made in accordance with GAAP. 
  

 3 

 1.16. “Commercialization Plan” shall mean the comprehensive plan for the
commercialization of a Collaboration Product, as more specifically described in Section 7.1 hereof. 
  
 1.17. “Competing Product” shall mean a non-Antibody-based antagonist of TGF-ß owned, controlled, developed or marketed by Genzyme
or its Affiliates for any use other than an Ophthalmic Application (i) that would compete with a Collaboration Product and (ii) the manufacture, use or sale of which (a) would infringe a claim within the CAT Program Patent Rights in the country in
which such product is manufactured, used or sold, or (b) is based on the CAT Program Technology. 
  
 1.18. “Development Costs” with respect to a Collaboration Product shall mean the variable costs and fixed costs properly incurred by the
Parties with respect to work performed by the Parties and their Affiliates and subcontractors in connection with the conduct of the Development Plan for such Collaboration Product, including without limitation (a) direct, out-of-pocket external
costs, including clinical grants, clinical laboratory fees, positive controls and the cost of studies conducted and services provided by contract research organizations and individuals, consultants, toxicology contractors, and manufacturers
necessary or useful for the purpose of obtaining Regulatory Approvals for such Collaboration Product, (b) amounts properly incurred by the Parties with respect to research and development and pre-commercialization sales and marketing efforts as set
forth in the Development Plan for such Collaboration Product, including without limitation the efforts of the Parties to develop a process for the manufacture of such Collaboration Product and the Fully Absorbed Cost of Goods for batches of such
Collaboration Product manufactured and supplied for use in preclinical and clinical trials and pre-commercialization activities, (c) costs related to data management, statistical designs and studies, document preparation and other expenses
associated with the clinical testing program for such Collaboration Product, (d) costs for preparing, submitting, reviewing or developing data or information for the purpose of submission of applications to obtain Regulatory Approvals for such
Collaboration Product, (e) a pro rata share of license fees, milestone payments and other amounts paid to Third Parties (including consultants) as a result of performance of the Development Plan, allocated based on the proportion of such
costs directly attributable to such Collaboration Product, and (f) a pro rata share of costs relating to the prosecution and maintenance of the CAT Patent Rights, the CAT Program Patent Rights, the CAT Background Patent Rights, the Genzyme
Patent Rights, the Genzyme Program Patent Rights and the Joint Patent Rights, allocated based on the proportion of such costs directly attributable to such Collaboration Product. For the avoidance of doubt, Development Costs shall exclude any
transfer pricing adjustments or taxes payable by a Party to one of its Affiliates in connection with such Affiliates’ performance of activities under a Development Plan. For purposes of this Section 1.18, “variable costs” shall
be deemed to be the cost of labor, raw materials, supplies and other resources directly consumed in the conduct of the Development Program and the manufacture of the Collaboration Product for use in preclinical and clinical trials and
pre-commercialization activities. For purposes of this Section 1.18, “fixed costs” shall be deemed to be the cost of facilities, utilities, insurance, facility and equipment depreciation and other fixed costs directly related to the
conduct of the Development Program and the manufacture of the Collaboration Product for use in preclinical and clinical trials and pre-commercialization activities, allocated based upon the proportion of such costs directly attributable to support
of the 

  

 4 

 
Development Program and the manufacture of the Collaboration Product for use in preclinical and clinical trials and pre-commercialization activities or by
such other method of cost allocation as may be approved by the Steering Committee. All cost determinations made hereunder shall be made in accordance with GAAP. 
  

1.19. “Development Plan” shall mean the comprehensive plan and budget for the development of a Collaboration Product under the
Development Program, as more specifically described in Section 5.1.2 hereof. 
  
 1.20. “Development Program” shall mean the preclinical and clinical development of Collaboration Products, including the preparation and filing of all applications for Regulatory Approvals for each
Collaboration Product. 
  
 1.21 “Effective Date”
shall mean September 27, 2000. 
  
 1.22. “EMEA”
shall mean the European Medicines Evaluation Agency, or any successor agency with responsibilities comparable to those of the European Medicines Evaluation Agency. 
  
 1.23. “Expert’s Decision” shall mean the procedure for resolving disputes set forth in Schedule
1.23. 
  
 1.24. “External Products” shall
mean, individually and collectively, Competing Products and Genzyme Products. 
  
 1.25. “FDA” shall mean the U.S. Food and Drug Administration or any successor agency with responsibilities comparable to those of the U.S. Food and Drug Administration. 
  
 1.26. “Field” shall mean all in vivo, ex vivo
and in vitro uses of Collaboration Products for therapeutic, diagnostic, prophylactic and monitoring applications in the management of human disease, excluding Ophthalmic Applications. 
  
 1.27. “Final Marketing Approval” shall mean receipt by
Genzyme of final approval by either (i) the FDA of a BLA for a Collaboration Product or an External Product, as the case may be, or (ii) the EMEA of both an MAA and pricing for a Collaboration Product or an External Product, as the case may be.

  
 1.28. “First Commercial Sale” shall mean the
first sale for consideration following receipt of Final Marketing Approval of a Collaboration Product or an External Product, as applicable. 
  
 1.29. “Fully Absorbed Cost of Goods” with respect to units of a particular Collaboration Product shall mean (a) the variable costs and
fixed costs properly incurred by a Party associated with the manufacture (inclusive of finishing processes including filling, packaging, labeling and/or other preparation), quality assurance, quality control and other testing, storage and shipping
of batches of such units of Collaboration Product or (b) if such units 

  

 5 

 
or portions of Collaboration Product are not manufactured by a Party or an Affiliate thereof, the amounts paid to the vendor plus costs associated with
acquisition from such vendor. For purposes of this Section 1.29, “variable costs” shall be deemed to be the cost of labor, raw materials, supplies and other resources directly consumed in the manufacture, quality assurance, quality
control and other testing, storage and shipping of batches of such Collaboration Product. For purposes of this Section 1.29, “fixed costs” shall be deemed to be the cost of facilities, utilities, insurance, facility and equipment
depreciation and other fixed costs directly related to the manufacture, quality assurance, quality control and other testing, storage and shipping of batches of such Collaboration Product, as well as amounts paid to Third Parties as a result of the
manufacture, use or sale of such units of Collaboration Product. Fixed costs shall be allocated to such Collaboration Product based upon the proportion of such costs directly attributable to the support of the manufacturing, quality assurance,
quality control and other testing, storage and shipping processes for such Collaboration Product. If a facility is used to manufacture Collaboration Products and products for other programs of a Party or an Affiliate thereof, fixed costs shall be
allocated in proportion to the use of such facility for the manufacture of Collaboration Products and products for such other programs. Fully Absorbed Cost of Goods shall exclude all costs otherwise reimbursed pursuant to this Agreement. Except as
otherwise provided in this Agreement, all cost determinations made hereunder shall be made in accordance with GAAP. 
  
 1.30. “GAAP” shall mean United States generally accepted accounting principles, consistently applied. 
  
 1.31. “Genzyme Patent Rights” shall mean all Patent Rights
owned or controlled by, or licensed (with the right to sublicense) to, Genzyme during the term of this Agreement (other than the Genzyme Program Patent Rights), to the extent such Patent Rights relate to the research, development, manufacture or
commercialization of Collaboration Products for use in the Field. The Genzyme Patent Rights existing as of the Effective Date are listed in Schedule 1.31 hereto. 
  
 1.32. “Genzyme Product” shall mean any non-Antibody-based antagonist of TGF-ß owned, controlled,
developed or marketed by Genzyme or its Affiliates for any use other than an Ophthalmic Application, the manufacture, use or sale of which would infringe a claim within the CAT Patent Rights in the country in which such product is manufactured, used
or sold. 
  
 1.33. “Genzyme Program Patent
Rights” shall mean the Patent Rights that claim Genzyme Inventions (as such term is defined in Section 9.1.1 hereof). 
  
 1.34. “Genzyme Technology” shall mean Technology owned or controlled by, or licensed (with the right to sublicense) to Genzyme during the
term of this Agreement, to the extent that such Technology relates to the research, development, manufacture or commercialization of Collaboration Products for use in the Field. 
  
 1.35. “Insolvency Event” shall mean, in relation to a Party, that an order is made or a resolution passed
for the liquidation, administration, winding-up, bankruptcy or dissolution of that entity (otherwise than for the purposes of a solvent amalgamation or reconstruction) or an administrative or other receiver, manager, trustee, liquidator,
administrator, or similar officer is 

  

 6 

 
appointed over all or any substantial part of the assets or revenues of the entity or that entity enters into or proposes any composition or arrangement with
its creditors generally or anything analogous to the foregoing occurs in any applicable jurisdiction, except in the case of a petition in bankruptcy filed involuntarily against a Party in the United States or any statutory demand or winding-up
petition is served on a Party in the United Kingdom, if such petition or demand is dismissed within sixty (60) days of the date of its filing. 
  
 1.36. “Inventions” shall mean all writings, inventions, discoveries, improvements and other technology (including without limitation any
proprietary biological or other materials, compounds or reagents and computer software), whether or not patentable or copyrightable and any patent applications, patents or copyrights based thereon, that are discovered made or conceived by either
Party during and in connection with the Program. 
  
 1.37.
“Integra” shall mean Integra Lifesciences Corporation and any successor in title thereto. 
  
 1.38. “Joint Patent Rights” shall mean the Patent Rights that claim Joint Inventions (as such term is defined in Section 9.1.1 hereof).

  
 1.39. “Joint Technology“ shall mean all
Technology discovered, made or conceived during and in connection with the Program jointly by employees of Aptein or one of its Affiliates and Genzyme, or others acting on their behalf. 
  
 1.40. “License Rights” shall mean the rights granted by Aptein to Genzyme pursuant to Sections 3.1.1(b)(ii)
and (iii) below. 
  
 1.41. “MAA” shall mean a
Marketing Authorization Application or similar application filed with the EMEA after completion of human clinical trials to obtain marketing approval for a Collaboration Product or an External Product, as the case may be. 
  
 1.42. “Manufacturing Know-How” shall mean all information,
techniques, inventions, discoveries, improvements, practices, methods, knowledge, skill, experience and other technology, whether or not patentable or copyrightable, and any copyrights based thereon, relating to or necessary or useful for the
production, purification, packaging, storage and transportation of Collaboration Products, including without limitation manufacturing processes, specifications, acceptance criteria, manufacturing batch records, standard operating procedures,
engineering plans, installation, operation and process qualification protocols for equipment, validation records, master files submitted to the FDA and EMEA, process validation reports, environmental monitoring processes, test data (including
pharmacological, toxicological and clinical test data), cost data and employee training materials. 
  
 1.43. “Net Profits” for any period shall be equal to (a) the sum during such period of all revenues recognized and recorded by Genzyme
and its Affiliates during such period with respect to (i) the sale of Collaboration Products and (ii) the grant or practice of sublicenses to Third Parties for the manufacture, use, distribution or sale of Collaboration Products, less
(b) all expenses (including accruals legitimately chargeable against profits) incurred by the Parties 

  

 7 

 
during such period in connection with the Program, including without limitation expenses incurred in respect of Development Costs and Commercialization Costs
and facility and equipment depreciation costs not otherwise accounted for. All determinations made hereunder shall be made in accordance with GAAP. 
  
 1.44. “Net Sales” shall mean the gross amount billed or invoiced by (a) Genzyme or its Affiliates or sublicensees for the sale of each
External Product or (b) in the case the Program is terminated pursuant to Section 13.2.4, the terminating Party or its Affiliates or sublicensees for the sale of each Collaboration Product (each, a “Royalty-Bearing Product”), less
(i) discounts actually allowed (ii) credits for claims, allowances, retroactive price reductions or returned goods; (iii) prepaid freight charges; (iv) sales taxes or other governmental charges actually paid in connection with the sale (but
excluding what is commonly known as income taxes); and (v) brokerage, commissions and other fees paid to others for or in connection with the sale of a Royalty-Bearing Product. For purposes of determining Net Sales, a sale shall be deemed to have
occurred when payment is received for the sale. 
  
 With respect
to any transfers of Royalty-Bearing Products between a Party and its Affiliate, Net Sales shall be calculated based on the final sale of such Royalty-Bearing Product to an independent Third Party. In the event that a Party or its Affiliate receives
non-monetary consideration for any Royalty-Bearing Products, Net Sales shall be calculated based on the fair market value of such consideration. 
  
 In the case of Combination Products, Net Sales means the gross amount billed or invoiced on sales of such a Combination Product less the deductions set
forth above, multiplied by a proration factor. The prorated component value shall be mutually agreed upon by the Parties in writing prior to product launch of such a Combination Product. If all components of the Combination Product were sold
separately during the same or immediately preceding Royalty Period, the proration factor shall be determined by the formula [A / (A+B)], where A is the aggregate gross sales price of all Royalty-Bearing Product components during such period when
sold separately from the other essential functional components, and B is the aggregate gross sales price of the other essential functional components during such period when sold separately from the Royalty-Bearing Product components. 
  
 1.45. “Ophthalmic Application” shall mean all in
vivo, ex vivo and in vitro uses of Collaboration Products or External Products for therapeutic, diagnostic, prophylactic and monitoring applications in the management of diseases or conditions of the human eye and its related
structures including, but not limited to, the eyelids and the optic nerve. 
  
 1.46. “Patent Rights” shall mean United States and foreign patents, patent applications, provisional patent applications, certificates of invention and applications therefor, divisions, continuations
or continuations-in-part, or continuing prosecution applications, together with any extensions, registrations, confirmations, reissues, re-examinations, renewals, supplementary protection certificates and other forms of government-issued patent
protection directed to the inventions claimed in the foregoing. 
  

 8 

 1.47. “Percentage Interest” shall mean the Parties’ respective interests in the
Program, calculated in accordance with the formulae set forth in Schedule 1.47. 
  
 1.48. “Profitability Date” shall mean the first day of the calendar quarter immediately following the second consecutive calendar quarter in which Net Profits are positive. 
  
 1.49. “Program” shall mean the collaboration between Genzyme
and Aptein to develop and commercialize Collaboration Products described in this Agreement. 
  
 1.50. “Program Costs” shall mean all Program-related costs, including without limitation Development Costs and Commercialization Costs, in each case as such costs are incurred or accrued on or after
the Effective Date. 
  
 1.51. “Program Management
Team” shall mean the joint team composed of representatives of Aptein or its Affiliates and Genzyme described in Section 8.1.1 hereof. 
  
 1.52. “Regulatory Approvals” shall mean all approvals from regulatory authorities in any country required lawfully to market
Collaboration Products in any such country, including without limitation approval of any BLA, MAA, any establishment license application filed with the FDA, EMEA or other appropriate regulatory authority to obtain approval of the facilities and
equipment to be used to manufacture a Collaboration Product, and any product pricing approvals where applicable. 
  
 1.53. “Regulatory Scheme” shall mean the U.S. Public Health Service Act and the regulations, interpretations and guidelines promulgated
thereunder by the FDA or the regulatory scheme applicable to the Collaboration Products in any country other than the United States, as such statutes, regulations, interpretations and guidelines or regulatory schemes may be amended from time to
time. 
  
 1.54. “Royalty Period” shall mean the
partial calendar quarter commencing on the date of the First Commercial Sale of a Collaboration Product or an External Product, as applicable, and every complete or partial calendar quarter thereafter during which a Party and its Affiliates maintain
the right to sell Collaboration Products and External Products under this Agreement. 
  
 1.55. “Specifications” with respect to a Collaboration Product shall mean the written specifications for such Collaboration Product determined by the Program Management Team and approved by the
Steering Committee; provided that such specifications shall at all times comply with the relevant Regulatory Scheme in the country of sale and in the country of use. The Specifications may be amended from time to time by the Program
Management Team, provided that such amendments are approved by the Steering Committee or the written agreement of the Parties, as the case may be, and subsequently approved by the relevant regulatory authorities. Copies of such Specifications
shall be maintained by Genzyme and shall become a part of this Agreement as if incorporated herein. 
  

 9 

 1.56. “Steering Committee” shall mean the governing body of the Program composed of
representatives of Aptein or its Affiliates and Genzyme appointed as described in Section 8.3.1 hereof. 
  
 1.57. “Technology” shall mean inventions, trade secrets, copyrights, know-how, data and other intellectual property of any kind
(including without limitation any proprietary biological or other materials, compounds or reagents and computer software), but not including Patent Rights. 
  
 1.58. “Territory” shall mean all of the countries of the world. 
  
 1.59. “Third Party” shall mean any entity other than Parties and their respective Affiliates. 

 
 1.60. “Whittier Patent” shall mean U.S. Patent No.
5,958,411, together with any Patent Rights corresponding thereto. 
  
 ARTICLE 2. SCOPE AND STRUCTURE 
  
 2.1. Antibody
Collaboration. This Agreement describes the terms of a collaboration between Genzyme and Aptein to develop and commercialize Collaboration Products in the Field and throughout the Territory. The Parties will undertake the Development Program for
each Collaboration Product, with each of the Parties assuming responsibility for those portions of the Development Program allocated to it under this Agreement. Upon completion of the Development Program, Genzyme will manufacture or have
manufactured Collaboration Products in bulk active ingredient and in finished dosage form for commercial sale, and Genzyme will market and sell Collaboration Products in the Territory. Genzyme and Aptein will share the costs related to the
preclinical and clinical development of Collaboration Products, as well as the costs incurred in connection with the manufacturing, regulatory, commercialization and reimbursement activities conducted in connection with such Collaboration Products,
in the proportions set forth in this Agreement. Genzyme and Aptein shall share Net Profits in proportion to their respective Percentage Interests. 
  
 2.2. License Arrangement. This Agreement also describes the terms of a license arrangement under which Genzyme may develop and commercialize
External Products under certain intellectual property owned or controlled by Aptein and its Affiliates. Genzyme shall be solely responsible, at its expense, for the development and commercialization of External Products, and shall make milestone
payments and pay royalties to Aptein at such times and in such amounts set forth in Sections 4.5 and 4.6 of this Agreement. 
  
 2.3. Exclusive Relationship. Except as provided by Section 3.5 below, neither Party nor any of their Affiliates shall independently, or with a
Third Party, conduct research or development activities or grant a license or sublicense regarding, or engage in the manufacture, marketing, sale or distribution in the Territory of Collaboration Products in the Field during the term of the Program
other than as part of the Program. In addition, during the [***] following termination of the Program, neither (a) the breaching Party and its Affiliates in the case of 

  

 10 

 
termination pursuant to Section 13.2.1 hereof, (b) the terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.2 hereof and
(c) the non-terminating Party and its Affiliates in the case of termination pursuant to Section 13.2.3 hereof shall independently, or with a Third Party, conduct research regarding, or engage in the manufacture, marketing, sale or distribution in
the Territory of, Collaboration Products in the Field; provided, however, that in the event that this Agreement is terminated pursuant to Section 13.2.2 hereof and the non-terminating Party does not exercise its option under Section 13.3.2
hereof, then the restrictions set forth in this sentence shall not apply. 
  
 ARTICLE 3. GRANTS AND RESERVATIONS OF RIGHTS 
  
 3.1. License Grants. 
  
 3.1.1. Grants from Aptein. 
  
 (a) Exclusive
Grant. Except as otherwise expressly provided herein, Aptein hereby grants to Genzyme an exclusive, irrevocable (except as provided in Section 13.3 below and subject to Section 3.5 below), royalty-free right and license, with the right to grant
sublicenses, in the Territory under the CAT Patent Rights, the CAT Program Patent Rights, the CAT Technology, the CAT Program Technology, the Joint Patent Rights, the Joint Technology, and Manufacturing Know-How owned or controlled by Aptein and its
Affiliates, to develop, make, have made, use, offer for sale, sell, have sold, import, have imported, export, and have exported Collaboration Products in the Field and in the Territory. The Parties intend for the foregoing exclusive license to be
covered by a block exemption under applicable antitrust directives of the European Union. Accordingly, such license shall terminate (i) in the case of Patent Rights, on a claim-by-claim and a country-by-country basis upon the expiration, abandonment
or invalidation of claims under such Patent Rights in such country and (ii) in the case of Technology, when such Technology enters the public domain. 
  
 (b) Non-Exclusive Grants. Except as otherwise expressly provided herein, Aptein hereby grants to Genzyme: 
  
 (i) a non-exclusive, irrevocable (except as provided in Section 13.3
below), royalty-free right and license, with the right to grant sublicenses, in the Territory under the CAT Background Patent Rights solely to the extent necessary for Genzyme to develop, make, have made, use, offer for sale, sell, have sold, import
and export Collaboration Products in the Field and in the Territory; 
  
 (ii) a worldwide, non-exclusive, irrevocable (except as provided in Section 13.6 below), royalty-bearing right and license, with the right to grant sublicenses, under the CAT Patent Rights and the CAT Technology to develop, make, have made,
sell, offer for sale, have sold, import, have imported, export and have exported Genzyme Products; provided, however, that the foregoing license is limited solely to the CAT Patent Rights and CAT Technology in existence as of the Effective
Date and further limited in the case of the CAT Technology to the extent that such Technology is necessary to practice the CAT Patent Rights licensed under this paragraph; and 
  

 11 

 (iii) a worldwide, non-exclusive, irrevocable (except as provided in Section 13.6 below),
royalty-bearing right and license, with the right to grant sublicenses, under the CAT Program Patent Rights and the CAT Program Technology to develop, make, have made, sell, offer for sale, have sole, import, have imported, export and have exported
Competing Products. 
  
 3.1.2 Grants from Genzyme. Except
as otherwise expressly provided herein, Genzyme hereby grants to Aptein a non-exclusive, irrevocable (except as provided in Section 13.3 below), royalty-free right and license in the Field and in the Territory under Genzyme’s interest in the
Genzyme Patent Rights, the Genzyme Program Patent Rights, the Genzyme Technology, and the Manufacturing Know-How owned or controlled by Genzyme solely to the extent necessary to permit Aptein to perform its duties under this Agreement. The foregoing
license shall include the right to grant sublicenses to an Affiliate of Aptein solely for the purposes of permitting such Affiliate to perform duties allocated to Aptein under a Development or Commercialization Plan, provided that such Affiliate
shall not have the right to grant further sublicenses. 
  
 3.2.
Reservation of Rights by Aptein. Notwithstanding the licenses granted under Section 3.1.1(a), Aptein at all times reserves the rights under its interest in the CAT Patent Rights, the CAT Program Patent Rights, the CAT Technology, the CAT
Program Technology, the Joint Patent Rights, the Joint Technology, and Manufacturing Know-How owned or controlled by Aptein and its Affiliates (i) to make, have made and use Collaboration Products only for the internal research and development
purposes of Aptein and its Affiliates, (ii) to develop, make, have made, use, offer for sale, sell, have sold, import and export products outside of the Field, (iii) subject to Section 3.5 below, to develop, make, have made, use, offer for sale,
sell, have sold, import and export CAT Products, and (iv) to grant licenses to Third Parties for the foregoing purposes. 
  
 3.3. Assignment of Orphan Drug Designation. Except to the extent prohibited by the applicable Regulatory Scheme, Aptein hereby agrees to assign,
and shall cause its Affiliates to assign, to Genzyme any “orphan drug” designation (or similar designation outside of the United States) for Collaboration Products in the Field and in the Territory that Aptein or any of its Affiliates has
received or may receive during the term of the Program. 
  
 3.4
Burnham License. Genzyme acknowledges and agrees that, in accepting the grant of certain of the licenses hereunder, it shall be subject to and shall assume certain terms and conditions of the Burnham License (as such agreement may be amended
from time to time) as if those terms and conditions were imposed on Genzyme itself. These terms and conditions include, without limitation, the payment of royalties, the furnishing of reports, the retention of records, and audit rights. In the event
of any conflict or inconsistency between any applicable provision of this Agreement and the provisions of the Burnham License, the provisions of the Burnham License shall prevail. 
  
 3.5. CAT Products. Aptein and Genzyme acknowledge and agree that the initial Development Plan describes each broad
clinical or disease indication for which the Parties intend 

  

 12 

 
to develop Collaboration Products during the full term of such Development Plan. At any time after [***] Aptein (with the support of its representatives on
the Steering Committee) may make a proposal to Genzyme’s representatives on the Steering Committee to develop a Collaboration Product for an additional disease indication. If the Steering Committee accepts such proposal within [***] of receipt
thereof, the then-current Development Plan shall be amended accordingly. [***] Aptein and/or its Affiliates will be free to develop, manufacture and/or commercialize a Collaboration Product for such disease indication in the Field (a “CAT
Product”) independently of Genzyme, either by itself or with a Third Party, and such activities shall no longer be considered to be part of the Program. A CAT Product shall not be considered to be a Collaboration Product for purposes of
this Agreement. The Parties shall negotiate in good faith any license and royalty agreements necessary to permit Aptein to develop, manufacture and commercialize a CAT Product in accordance with this Section 3.5. Without limitation of the foregoing,
all up-front payments received by Aptein and/or its Affiliates from a Third Party with respect to the licensing of the CAT Patent Rights, CAT Program Patent Rights, CAT Background Patent Rights, CAT Technology, CAT Program Technology, Joint Patent
Rights, Joint Technology, or Manufacturing Know-How owned or controlled by Aptein and its Affiliates for use in developing, manufacturing or commercializing such CAT Product, and all subsequent license fees, milestones and royalty payments relating
to, or revenues generated from the sale of, such CAT Product, and any proceeds from the sale of all of the rights to such CAT Product, will be distributed in accordance with a formula to be mutually agreed upon by the Parties. [***]. 
  
 ARTICLE 4. PROGRAM FUNDING; PERCENTAGE INTEREST 
  
 4.1. Program Funding. In connection with the preparation of the
Development Plan for the period beginning on [***] and ending on [***] (the “[***] Development Plan”), the Parties have agreed upon a budget for the activities to be performed under the [***] Development Plan. Aptein hereby commits
to fund the following percentages of budgeted Program Costs set out in the [***] Development Plan for the period beginning on [***] and ending on [***] (the “Committed Funding Period”): (a) [***] of such Costs for the period
beginning on [***] and ending on [***] and (b) if Aptein, together with its Affiliates (including, for the avoidance of doubt, CAT), have cash and cash equivalents in excess of [***] in the aggregate at [***] of such Costs [***] for the period
beginning on [***] and ending on [***] and [***] of such Costs for the period beginning on [***] and ending on [***]. Notwithstanding the foregoing, Aptein shall have the option not to fund all or any portion of the Program Costs to which it has
committed in the previous sentence for the period beginning on [***] and ending on [***], but in such event Genzyme’s Percentage Interest will be adjusted upward in accordance with the principles set out in Schedule 1.47. To the extent
that actual Program Costs during the Committed Funding Period exceed the amounts set out in the budget included in the [***] Development Plan, whether or not such excess required Steering Committee approval pursuant to Section 5.1.3, Aptein may, at
its discretion, fund in lieu of such percentage an absolute amount equal to the amount it would have funded had the actual budget been the same as the one set out in the [***] Development Plan. Conversely, to the extent that actual Program Costs
during the Committed Funding Period are less than the amounts set out in the budget included in the [***] Development Plan, the Parties will discuss in good faith an equitable extension of the Committed Funding Period. Genzyme hereby commits to fund
the remaining percentage of Program Costs during such period. 
  

 13 

 Subject to the funding commitments set forth in the preceding paragraph for the Committed Funding Period,
in connection with each annual update to the Development Plan described in Section 5.1.3 below and until the Profitability Date, Aptein will commit to fund a specified percentage (not to exceed [***]) of Program Costs for the second year of the
rolling four-year budget (because it would have previously committed to the first year of such budget), and Genzyme will fund the remaining budgeted amount; provided, however, that if the actual budget approved for the second year of the
rolling four-year budget is higher than what had been projected when Aptein committed to fund a percentage of such budget, Aptein may, at its discretion, fund in lieu of such specified percentage an absolute amount equal to the amount it would have
funded had the actual budget been the same as what had been projected. Following the Profitability Date, Genzyme will fund Program Costs from operations. All operating losses recognized in any calendar quarter after the Profitability Date will be
funded by the Parties in accordance with their Percentage Interests; provided, however, if Aptein elects not to fund such losses then its Percentage Interest shall be adjusted downward in accordance with the principles set out in Schedule
1.47. Each Party hereby undertakes to fund such percentage of the Program Costs incurred by the Parties in accordance with the provisions of this Section 4.1. The Parties’ respective funding commitments shall be satisfied in the manner set
forth in Section 4.2 below. 
  
 4.2. Payments. 

 
 4.2.1. Initial Payment. Within five (5) business days of the
Effective Date, (a) each Party shall pay the other, by payment or offset against amounts then due from the other, an amount equal to the Program Costs budgeted to be incurred by the Parties during the period beginning on the Effective Date through
and including the end of the calendar quarter in which the Effective Date occurs and (b) Genzyme shall pay Aptein [***] in consideration for the grant of rights under the Whittier Patent, which amount shall not be considered a Program Cost.

  
 4.2.2. Quarterly Payments. With respect to each full
calendar quarter after the Effective Date, each Party shall pay the other, by payment or offset against amounts then due from the other, in advance, an amount equal to the Program Costs budgeted to be incurred by the Parties in any then-current
Development Plan or Commercialization Plan for such calendar quarter. 
  
 4.2.3. Quarterly Statements; Quarterly Reconciliation. Within five (5) business days after the end of each of the first three (3) calendar quarters of each year and within two (2) calendar weeks after the end of each calendar year,
each of Genzyme and Aptein shall provide the other Party with a detailed itemization of its Program Costs as follows: the itemization for the first two months of each calendar quarter shall be the Program Costs actually incurred during those two
months and the itemization for the third month of each quarter may include estimates. The itemization for each subsequent calendar quarter shall then include a reconciliation of all estimated amounts reported during the prior quarter. Each Party
shall provide the other Party with estimates of such costs upon the reasonable request of the other Party prior to the dates such statements are due. Within thirty (30) business days following receipt of the statement of actual 

  

 14 

 
Program Costs provided by each of Genzyme and Aptein, each Party shall pay the other, by payment or offset against amounts then due from the other, its share
of any actual Program Costs shown thereon and not yet paid for which such Party has assumed funding responsibility pursuant to Section 4.1 above, but only to the extent that such amount, together with all prior contributions to date during such
year, does not exceed [***] of the total Program Costs budgeted year-to-date through the end of the quarter to which such statement relates (except to the extent such excess is approved by the Steering Committee pursuant to Section 5.1.3 hereof). If
the aggregate amount stated to be due from a Party in such quarterly statements for actual Program Costs is less than the amount already contributed by such Party with respect to budgeted Program Costs for such quarter, such excess shall be credited
against the next successive quarterly payment due from such Party hereunder. 
  
 4.3. Enforceability of Sections 4.1 and 4.2. The agreements regarding funding commitments set forth in Sections 4.1 and 4.2 above are by and between, and for the benefit of, Genzyme, Aptein and their respective
Affiliates only, and are not enforceable by any Third Party. 
  
 4.4. Profit Sharing. Within forty-five (45) days following the end of each calendar quarter following the Profitability Date, Genzyme shall deliver to Aptein a report setting forth all information necessary to calculate the amounts
due to Aptein pursuant to this Section 4.4. All such reports shall be considered confidential Information of Genzyme and shall be subject to audit rights as set forth in Section 4.12 below, mutatis mutandis. If no payments are due to Aptein,
the report shall so state. Concurrent with each report, and subject to Section 4.10 below, Genzyme shall pay to Aptein an amount equal to the product obtained by multiplying aggregate Net Profits for such quarter by Aptein’s Percentage
Interest. The Parties will equitably adjust the foregoing formula in the event that Aptein or any of its Affiliates is required under the terms of any agreement with a Third Party to make payments to such Third Party on Genzyme’s behalf in
respect of the sale of Collaboration Products. 
  
 4.5.
Milestone Payments. Genzyme hereby agrees to pay the following amounts to Aptein within ten (10) business days of the occurrence of the following events: 
  
 (a) [***] upon commencement by Genzyme or an Affiliate of the first Phase I clinical trial of a Genzyme
Product classified as a “biologic” by the FDA; 
  
 (b) [***] upon commencement by Genzyme or an Affiliate of the first Phase I clinical trial of a Genzyme Product classified as a “drug” by the FDA; 
  
 (c) [***] upon receipt by Genzyme or an Affiliate of the
first Final Marketing Approval of a Genzyme Product classified as a “biologic” by the FDA; and 
  
 (d) [***] upon receipt by Genzyme or an Affiliate of the first Final Marketing Approval of a Genzyme Product classified as a
“drug” by the FDA. 
  

 15 

 For the avoidance of doubt, the payments set forth above shall be made only with respect to the first
Genzyme Product to accomplish such milestone and no milestone shall be payable by Genzyme more than once. 
  
 4.6 Royalties. 
  
 4.6.1. Genzyme Products. 
  
 (a) In partial consideration for the grant by Aptein of the License Rights, Genzyme shall pay Aptein a royalty of [***] on Net Sales of Genzyme Products
which are covered by an issued and unexpired claim within the CAT Patent Rights in the country of sale, payable on a country-by-country basis until the expiration in such country of all issued patents within the CAT Patent Rights; provided,
however, that if a claim within the CAT Patent Rights issues in a country within [***] of the filing date of the patent application containing such claim, Genzyme shall pay Aptein the foregoing royalty as of the date on which such patent
application was filed (or, if later, the date of First Commercial Sale of a Genzyme Product), with such retroactive royalty payable over the [***] period beginning with the date on which such claim was issued; and provided, further, that if a
claim within the CAT Patent Rights issues in a country after [***] of the filing date of the patent application containing such claim, Genzyme shall pay Aptein [***] of the foregoing royalty as of the date on which such patent application was filed
(or, if later, the date of First Commercial Sale of a Genzyme Product), with such retroactive royalty payable over the [***] period beginning with the date on which such claim was issued. The payment of royalties hereunder shall be limited to only
[***] royalty payment with respect to a single unit of Genzyme Product regardless of the number of claims within the CAT Patent Rights such Genzyme Product, but for the License Rights, would have infringed. 
  
 (b) In the event Aptein or one of its Affiliates successfully negotiates a
decrease in the royalty rate payable under the Burnham License after the Effective Date, the royalty payable by Genzyme on Net Sales of Genzyme Products shall increase, for the length of time Aptein would be obligated to pay royalties under such
agreement (notwithstanding Genzyme’s obligation under Section 4.6.4 to pay such royalties on Aptein’s behalf), by an amount equal to [***] of the royalty rate decrease negotiated by Aptein or its Affiliate (the “Incremental
Royalty”). If Genzyme is required to pay royalties to Third Parties (other than under the Burnham License or agreements between Genzyme and Third Parties in existence as of the Effective Date) in order to make, use or sell Genzyme Products,
then Genzyme shall be entitled to reduce the amount of aggregate Incremental Royalties payable to Aptein by [***] of the amount of such Third Party royalties; provided, however, that the Incremental Royalties shall not be reduced by more than
[***]. For the avoidance of doubt, an example of the application of this Section 4.6.1 is set forth in Schedule 4.6.1. 
  
 4.6.2. Competing Products. In partial consideration for the grant by Aptein of the License Rights and in addition to any royalties payable by
Genzyme pursuant to Section 4.6.1, Genzyme shall pay Aptein a royalty of [***] on Net Sales of Competing Products which are covered by an issued and unexpired claim within the CAT Program Patent Rights in the country of sale, payable on a
country-by-country basis until the later of: (i) the expiration in such country of all issued patents within the CAT Program Patent Rights or (ii) the tenth (10th) 

  

 16 

 
anniversary of the First Commercial Sale of such Competing Product in such country; provided, however, that if a claim within the CAT Program Patent
Rights issues in a country within [***] of the filing date of the patent application containing such claim, Genzyme shall pay Aptein the foregoing royalty as of the date on which such patent application was filed (or, if later, the date of First
Commercial Sale of a Competing Product), with such retroactive royalty payable over the [***] period beginning with the date on which such claim was issued; provided, further, that if a claim within the CAT Program Patent Rights issues in a
country after [***] of the filing date of the patent application containing such claim, Genzyme shall pay Aptein [***] of the foregoing royalty as of the date on which such patent application was filed (or, if later, the date of First Commercial
Sale of a Competing Product), with such retroactive royalty payable over the [***] period beginning with the date on which such claim was issued; and provided, further, that if such Competing Product is not covered by an issued and unexpired
claim within the CAT Program Patent Rights in such country but is based on the CAT Program Technology, the foregoing royalty shall be reduced to [***] of Net Sales. The payment of royalties hereunder shall be limited to only one royalty payment with
respect to a single unit of Competing Product regardless of the number of claims within the CAT Program Patent Rights such Competing Product, but for the License Rights, would have infringed and regardless of whether such Competing Product is both
covered by an issued claim within the CAT Program Patent Rights and is based on the CAT Program Technology. 
  
 4.6.3. Whittier Patent. In partial consideration for the grant by Aptein of the License Rights, Genzyme shall pay Aptein a royalty of [***] on Net
Sales of External Products which are covered by an issued and unexpired claim within the Whittier Patent in the country of sale, payable on a country-by-country basis until the expiration in such country of all issued patents within the Whittier
Patent. The payment of royalties hereunder shall be limited to only one royalty payment with respect to a single unit of an External Product regardless of the number of claims within the Whittier Patent such External Product, but for the License
Rights, would have infringed. 
  
 4.6.4. Third Party
Payments. Genzyme hereby undertakes: (i) to pay all royalties, sublicense fees and other costs or expenses payable to Third Parties associated with the sale of Genzyme Products by Genzyme or its Affiliates and sublicensees, either directly to
such Third Party or through Aptein or its Affiliates; (ii) to pay all amounts payable to Burnham pursuant to Section 4.2.2 of the Burnham License, either directly to such Third Party or through Aptein or its Affiliates; and (iii) to comply with the
Burnham License in making such payments in accordance with Section 3.4 above. 
  
 4.6.5. Payments and Reports. Within forty-five (45) days following the conclusion of each Royalty Period, Genzyme shall deliver to Aptein a report setting forth all information necessary to calculate the amount
of royalties due to Aptein pursuant to this Section 4.6. All such reports shall be considered confidential Information (as defined in Section 10.1) of Genzyme, and shall be subject to audit rights as set forth in Section 4.12 below, mutatis
mutandis. If no royalties are due to Aptein for any Royalty Period, the report shall so state. Concurrent with each report, Genzyme shall remit to Aptein any royalty payment due for the applicable Royalty Period. 
  

 17 

 4.7 Burnham License. If Aptein or any of its Affiliates is required to pay cash or other
consideration to reduce the royalty rates payable under the Burnham License following the Effective Date, Genzyme shall pay Aptein, within thirty (30) days following receipt of a written invoice therefor, in an amount equal to [***] of the amounts
paid by Aptein or its Affiliate to reduce such royalty rates; provided, however, in no event shall Genzyme be required to pay more than [***] in the aggregate pursuant to the provisions of this paragraph. In the event that Aptein or any of
its Affiliates pays non-monetary consideration (e.g., stock) to reduce the royalty rates payable under the Burnham License, Genzyme’s obligations under this Section 4.7 shall be calculated based on the fair market value of such
consideration. No amounts paid by Aptein, its Affiliates or Genzyme pursuant to this Section 4.7 shall be considered Program Costs. 
  
 4.8. Payments in United States Dollars; Method of Payment. All payments due under this Agreement shall be payable in U.S. dollars. All payments
under this Agreement shall be made by certified or bank check or by wire transfer in immediately available funds to such account(s) as the Party owed such payment may designate in writing to the Party making such payment, provided that such accounts
are located outside of the United Kingdom. 
  
 4.9. Payments in
Other Currencies. If by law, regulation, or fiscal policy of a particular country, conversion into United States dollars or transfer of funds of a convertible currency to the United States is restricted or forbidden, Genzyme shall give Aptein
prompt written notice of such restriction, which notice shall satisfy the forty-five (45) day payment deadline described in Sections 4.4 and 4.6.5. Genzyme shall pay any amounts due Aptein through whatever lawful methods Aptein reasonably
designates; provided, however, that if Aptein fails to designate such payment method within thirty (30) days after Aptein is notified of the restriction, Genzyme may deposit such payment in local currency to the credit of Aptein in a
recognized banking institution selected by Genzyme and identified by written notice to Aptein, and such deposit shall fulfil all obligations of Genzyme to Aptein with respect to such payment. 
  
 4.10. Withholding and Similar Taxes. Any withholding of taxes levied
by tax authorities on the payments hereunder shall be deducted by the paying Party from the sums otherwise payable by the paying party hereunder for payment to the proper tax authorities on behalf of the receiving Party and shall be paid by the
paying Party to such proper tax authorities. The Parties agree to cooperate with each other in the event a Party claims exemption from such withholding or seeks deductions under any double taxation or other similar treaty or agreement from time to
time in force, such cooperation to consist of providing receipts of payment of such withheld tax or other documents reasonably available to the cooperating Party. 
  
 4.11. Late Payments. Any payments by Genzyme or Aptein that are not paid on or before the date such payments are due
under this Agreement shall bear interest, to the extent permitted by law, at the Prime Rate of interest as reported by the Chase Manhattan Bank, New York, New York, on the date payment is due, with interest calculated based on the number of days
that payment is delinquent. 
  
 4.12. Books of Account;
Audit. Each Party shall keep and maintain proper and complete records and books of account documenting (i) all Program Costs incurred by it and its Affiliates and (ii) all information required to enable Aptein to determine royalties and other

  

 18 

 
amounts payable to Aptein hereunder. Each Party shall permit independent accountants retained by the other Party to have access to its records and books for
the sole purpose of determining (i) the appropriateness of Program Costs charged by the non-auditing Party hereunder and (ii) verifying the profit sharing and royalty reports delivered pursuant to Sections 4.4 and 4.6.5 above. Such examination shall
be conducted during regular business hours and upon reasonable notice, at the auditing Party’s own expense and no more than once in each calendar year during the term of this Agreement and once during the three (3) calendar years following the
termination hereof. If such examination reveals that such Program Costs or royalties have been misstated, any adjustment shall be promptly refunded or paid, as appropriate. The auditing Party shall pay the fees and expenses of the accountant engaged
to perform the audit, unless such audit reveals an overcharge, accrual or underpayment of [***] or more for the period examined, in which case the audited Party shall pay all reasonable costs and expenses incurred by the auditing Party in the course
of making such determination, including the fees and expenses of the accountant. 
  
 ARTICLE 5. THE DEVELOPMENT PROGRAM 
  
 5.1. Conduct of the Development Program. 
  
 5.1.1. General. The Parties each agree to collaborate diligently in the development of Collaboration Products in the Field and to use commercially reasonable and diligent efforts to develop, obtain Regulatory Approvals for and bring
to market Collaboration Products in the Field and in the Territory as soon as practicable, all in accordance with the Development Plan and the Commercialization Plan for such Collaboration Products. The Parties agree to execute and substantially
perform and to cooperate with each other in carrying out the Development Plan and the Commercialization Plan for each Collaboration Product. Neither Party shall be required to undertake activities in furtherance of the Development Plan or
Commercialization Plan if the other Party is not meeting its Program funding commitments set forth in this Agreement. As used in this Agreement, the term “commercially reasonable and diligent efforts” will mean that level of effort
which, consistent with the exercise of prudent scientific and business judgment, is or would be applied by the Party in question to its or its Affiliates’ other therapeutic products at a similar stage of development and with similar commercial
potential, and in no event shall that level of effort be less than that required under applicable provisions of the Burnham Agreement. 
  
 5.1.2. Development Plan. The Development Program shall be conducted by the Parties under a rolling [***] Development Plan which shall describe the
proposed overall program of development for each Collaboration Product, including preclinical studies, toxicology, formulation, clinical trials and regulatory plans and other key elements necessary to obtain Regulatory Approvals for such
Collaboration Product. The Development Plan shall include a summary of estimated Development Costs expected during the development process and a detailed description of and budget for all development activities proposed for each calendar year for
each Collaboration Product. 
  
 5.1.3. Updated Development
Plan. The 2003 Development Plan is attached hereto as Schedule 5.1.3. The Development Plan shall be updated annually by Genzyme, in 

  

 19 

 
consultation with Aptein, and submitted to the Steering Committee for review and approval not later than October 31 of each year during the Development
Program. Each such updated Development Plan shall include (a) an overall development plan for each Collaboration Product which sets forth all major development tasks remaining to be accomplished prior to submission of filings for Regulatory
Approvals, (b) a detailed description for the development and pre-commercialization activities proposed for the following [***] calendar years, and (c) a detailed, rolling [***] financial forecast containing a committed budget for the first calendar
year and good faith estimates of the budget for the following [***] calendar years. Each such updated Development Plan approved by the Steering Committee shall be signed by an authorized representative of each of Genzyme and Aptein. The members of
the Program Management Team shall actively consult with one another throughout the term of the Development Plan so as to adjust the specific work performed under the Development Plan to conform to evolving developments in technology and the results
of the development work performed. While minor adjustments to the Development Plan may be made from time to time upon approval of the Program Management Team, significant changes in the scope or direction of the work and any changes in funding
exceeding [***] of the total amount budgeted in any calendar year for the Development Program must be approved by the Steering Committee, in the absence of which approval the most recently approved Development Plan and budget shall remain in effect.
Notwithstanding the foregoing, if the Steering Committee does not approve the budget increase and such increase is necessitated by a significant change in an activity for which one of the Parties has primary responsibility as described in Section
5.1.4. below, the Party responsible for such activity may independently determine to increase the applicable budget. The other Party shall then have the option, exercisable within (30) days of the decision to increase the applicable budget, to fund
a percentage of such increased Development Costs at a level not to exceed the percentage of such costs being funded by such Party during such year. If such budget increase is necessitated by an activity for which the Parties share joint
responsibility, either Party may choose to fund such activity on its own, provided that such funding will only be considered a Development Cost if the aggregate amount funded by such Party in a calendar year under this sentence does not exceed
[***]. 
  
 5.1.4. Execution and Performance. The
Development Program shall allocate between the Parties responsibility for each of the activities described therein. Each Party may subcontract portions of the activities allocated to it under a Development Plan to any of its Affiliates or to a Third
Party with the prior approval of the other Party (such Affiliate or Third Party being referred to herein as a “Permitted Subcontractor”), provided that (i) the subcontracting Party shall be responsible for the performance of its
Permitted Subcontractors and (ii) all Inventions discovered, made or conceived by each Permitted Contractor in the course of the performance of such activities shall be assigned to the subcontracting Party in a manner consistent with Sections 9.1.1
and 9.1.3 below and licensed to the other Party pursuant to Article 3 above. The Parties shall use, and shall cause their Permitted Subcontractors to use, commercially reasonable and diligent efforts to conduct the activities described in the
Development Plan and in so doing shall prepare and maintain proper records, including laboratory notebooks prepared and maintained in accordance with commercial scientific practice, detailing such activities. The Parties acknowledge and agree that
each Development Plan shall allocate primary responsibility for various activities as follows: 
  

	 	(a)	Antibody engineering: Aptein; provided, however, if the process selected by Aptein for developing a human antibody does not result within a reasonable period of time in a
human antibody with properties acceptable to both Parties, then decision-making with respect to such humanization activities will become joint; 

  

 20 

	 	(b)	Preclinical development: Joint; 

  

	 	(c)	Product and process development: Joint; 

  

	 	(d)	Clinical development: Genzyme; 

  

	 	(e)	Biostatistics: Genzyme; 

  

	 	(f)	Regulatory: Genzyme; and 

  

	 	(g)	Manufacturing, quality control and quality assurance: Genzyme. 

  
 Notwithstanding the foregoing allocations of responsibility, the Program Management Team will coordinate and supervise activities under the Development Plan. 

 
 5.1.5. Attendance at Regulatory Meetings. Each Party shall provide
the other Party with prior notice of all meetings with regulatory authorities regarding any Collaboration Product. Except as otherwise provided herein, each Party and their respective Affiliates shall have the right to have representatives present
at all such meetings. 
  
 5.2. Development Information.

  
 5.2.1. Reports and Information Exchange. Genzyme shall
own all clinical trial data accumulated from all clinical trials of Collaboration Products conducted as part of the Program or otherwise funded or partially funded by the Parties. Each Party shall use, and shall cause its Permitted Subcontractors to
use, commercially reasonable and diligent efforts to disclose to the other Party all material information relating to any Collaboration Product promptly after it is learned or its materiality is appreciated. The Party performing or supervising
clinical trials of Collaboration Products in accordance with the Development Plan shall maintain, and shall cause its Permitted Subcontractors to maintain, the database of clinical trial data accumulated from all clinical trials of Collaboration
Products and of adverse reaction information for all such Collaboration Products. Such database shall be maintained in accordance with the Medical Dictionary for Regulatory Activities standard, as in effect from time to time. Each Party shall also
keep the Program Management Team informed as to its or its Permitted Subcontractors’ progress in the Development Plan. All protocols for clinical trials to be conducted, and all product registration plans for Collaboration Products shall be
submitted to the Program Management Team for review and comment by the Program Management Team prior to filing of such protocols or registrations with any regulatory agency. Within sixty (60) days following the end of each calendar quarter during
the Development Program, each Party shall provide the other Party with a reasonably detailed written report which shall describe the progress to date of all activities for which such Party and its Affiliates were allocated responsibility during such
quarter under the Development Plan. 
  

 21 

 5.2.2. Adverse Reaction Reporting. Each Party shall notify, and shall cause its Permitted
Subcontractors to notify, the other Party of any adverse reaction information relating to any Collaboration Product, CAT Product, or Antibody-based antagonist of TGF-ß developed for an Ophthalmic Application as necessary for compliance with
regulatory requirements and in accordance with procedures to be established by the Program Management Team no later than the date on which the first clinical trial for such Collaboration Product, CAT Product, or Antibody-based based antagonist of
TGF-ß developed for an Ophthalmic Application is initiated. “Adverse reaction information” includes without limitation information relating to any experience that (a) suggests a significant hazard, contraindication, side
effect or precaution, (b) is fatal or life threatening, (c) is permanently disabling, (d) requires or prolongs inpatient hospitalization, (e) involves a congenital anomaly, or (f) is one not identified in nature, specificity, severity or frequency
in the current investigator brochure or the United States labeling for the Collaboration Product. 
  
 5.2.3. Clinical and Regulatory Audits. Each Party shall permit, and shall cause its Permitted Subcontractors to permit, the other Party or the
representatives of the other Party or any applicable regulatory authority (including without limitation the FDA and the EMEA) to have access during regular business hours and upon reasonable advance notice, at the auditing Party’s own expense,
to the audited Party’s and its Permitted Subcontractors’ records and facilities relating to the Development Program for the purpose of monitoring compliance with current Good Clinical Practice and other applicable requirements of the
Regulatory Scheme. 
  
 5.3. Regulatory Approval Filings.
Genzyme shall be responsible for all activities relating to obtaining Regulatory Approvals for Collaboration Products in the Territory. Regulatory Approval filings in the Territory for the Collaboration Products and for the facilities used to
manufacture such Collaboration Products shall be filed in the name of Genzyme or its Affiliates, as reasonably determined by Genzyme. Prior to submission to the FDA, EMEA, or other applicable regulatory authority, the Parties, through the Program
Management Team, shall (i) consult, cooperate in preparing and mutually agree on the content and scope of the Regulatory Approval filings and (ii) prepare technical agreements outlining the responsibilities of the Parties regarding compliance with
the applicable Regulatory Scheme. 
  
 5.4. Clinical Data.
In all agreements with Permitted Subcontractors involving the development of preclinical or clinical data for a Collaboration Product, Genzyme and Aptein shall each require that such Permitted Subcontractors provide the other Party access to all
such data required to be disclosed to the Japanese Ministry of Health and Welfare, the FDA, the Committee of Proprietary Medicinal Products of the European Community, the EMEA or other regulatory agency, in each case with respect to Regulatory
Approvals. 
  
 5.5. Facilities Visits. Representatives of
each Party, its Affiliates, or any applicable regulatory authority (including without limitation the FDA and the EMEA) may visit, upon reasonable notice and in the presence of the other Party, all manufacturing sites and the sites of any clinical
trials or other experiments being conducted by the other Party and its Permitted 

  

 22 

 
Subcontractors in connection with the Development Program. Each Party shall, upon request of the other Party, cause appropriate individuals working on the
Development Program on its and its Permitted Subcontractors’ behalf to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.

  
 ARTICLE 6. MANUFACTURE AND SUPPLY 
  
 Subject to the terms and conditions of this Agreement, Collaboration Products
shall be manufactured and supplied for preclinical and clinical testing and for commercial sale upon the following terms and conditions. For purpose of this Article 6 and Article 12, the term “Collaboration Products” shall be deemed to
include Collaboration Products in bulk active ingredient and in finished dosage form. 
  
 6.1. Process Development. The Parties will use, and shall cause their respective Permitted Subcontractors to use, commercially reasonable and diligent efforts to develop a process for the manufacture of each
Collaboration Product and to scale up that process to a scale sufficient to manufacture and supply (a) the anticipated demand for preclinical studies and clinical trials of such Collaboration Product in accordance with the projections set forth in
the Development Plan and (b) the anticipated market demand (plus a reasonable level of inventory) for such Collaboration Product at the time Regulatory Approval is obtained for such Collaboration Product in accordance with the projections set forth
in the Commercialization Plan for such Collaboration Product. The development of the process for the manufacture of Collaboration Products as well as the scale up of such process and all material issues incident to the development of the ability to
produce Collaboration Products for commercial purposes in sufficient quantity and in a timely manner will be within the purview of the Program Management Team, and all changes to the manufacturing process shall be subject to the approval of the
Program Management Team and any additional quality and regulatory personnel of the Parties whose approval is deemed necessary or desirable. 
  
 6.2. Manufacture and Supply of Collaboration Products. Genzyme shall, or shall engage one of its Affiliates or a Third Party to manufacture and
supply, Collaboration Products for preclinical and clinical activities and commercial sale. Manufacturing activities to be performed by an Affiliate or Third Party shall be performed pursuant to a supply agreement to be negotiated in good faith and
entered into by Genzyme and such Affiliate or Third Party. Genzyme shall, or shall cause its Affiliates or Third Parties engaged as contract manufacturers to, use commercially reasonable and diligent efforts to manufacture and supply each
Collaboration Product (i) for preclinical studies and clinical trials in quantities and within a time period sufficient to conduct the activities set forth in the Development Plan and (ii) to meet market demand for Collaboration Products at the time
Regulatory Approval is obtained for such Collaboration Product in accordance with the projections set forth in the Commercialization Plan for such Collaboration Product. Notwithstanding the foregoing, the Parties acknowledge and agree that [***]
shall initially supply Collaboration Products pursuant to [***] until such time as [***] determines to establish alternative arrangements for the manufacture and supply of Collaboration Products; provided, however, in so doing [***] shall
take no action that would result in a breach [***]. 
  

 23 

 6.3. Planning Meetings. The Parties recognize that detailed and continuing exchanges of
information shall be necessary in order to optimize the sale of Collaboration Products by Genzyme, consistent with their respective rights and responsibilities under this Agreement. To that end, Genzyme shall keep the Program Management Team
reasonably informed of any and all issues that arise affecting the production of Collaboration Products. The Program Management Team shall conduct a planning meeting at least once per quarter to review projected demand for Collaboration Products and
levels of commercial sales of the Collaboration Products in the Territory and address supply issues. 
  
 6.4 Facilities. Notwithstanding any provision of this Agreement to the contrary, the Parties acknowledge and agree that Aptein shall not bear any
costs relating to the construction by Genzyme of manufacturing facilities for a Collaboration Product (other than through depreciation and authorization included in Fully Absorbed Cost of Goods). 
  
 6.5 U.S. Manufacture. To the extent required by applicable law and the
Telios Agreements, Genzyme agrees that the Collaboration Products and Genzyme Products will be manufactured substantially in the United States, subject to such waivers as may be obtained from the U.S. Department of Health and Human Services or its
designee. 
  
 ARTICLE 7. SALES, MARKETING AND ADMINISTRATIVE
SERVICES 
  
 7.1. Commercialization Plans. The
commercialization of each Collaboration Product shall be governed by a Commercialization Plan which shall describe the overall plan for commercializing such Collaboration Product, including without limitation (a) a comprehensive marketing, sales,
pricing, manufacturing, distribution and licensing strategy for such Collaboration Product in all applicable countries, including the identification of any Third Parties engaged or to be engaged in connection with such activities and the
arrangements with them that have been or are proposed to be agreed upon (including policies and procedures for adjustments, rebates, bundling and the like), (b) estimated launch date, market and sales forecasts, in numbers of patients and local
currency, and competitive analysis for such Collaboration Product, (c) a detailed budget for the Commercialization Costs to be incurred in connection with performing such Commercialization Plan, and (d) production and inventory forecasts. Genzyme
shall be responsible for developing the Commercialization Plan in consultation with Aptein and for updating it annually. Genzyme shall provide Aptein a copy of each Commercialization Plan promptly following its completion. 
  
 7.2. Exclusive Engagement. Genzyme shall have the exclusive right to
market and sell Collaboration Products within the Territory for use within the Field and agrees (by itself or through its Affiliates) to use commercially reasonable and diligent efforts to establish each Collaboration Product in the markets, fulfil
market demand and meet the marketing and distribution goals set forth in the Commercialization Plan for such Collaboration Product. Genzyme’s diligence obligations under this Section 7.2 shall exist regardless of whether Genzyme is developing
or commercializing a Genzyme Product. 
  
 7.3. Marketing and
Distribution Expenses. All freight, insurance, duties and all other charges associated with shipment of the Collaboration Products shall be considered 

  

 24 

 
Commercialization Costs for such Collaboration Products only to the extent such costs are not charged to Genzyme’s customers. Genzyme’s ordinary
expenses incurred in the course of performing its marketing and distribution obligations hereunder shall constitute Commercialization Costs. 
  
 7.4. Responsibilities of Genzyme. Genzyme shall be solely responsible for all aspects of the marketing of the Collaboration Products in accordance
with the strategy, policies and procedures established in the Commercialization Plan. Genzyme shall comply with all applicable laws and regulations in connection with such activities, including but not limited to those related to
“off-label” promotion of biopharmaceutical products. 
  
 7.5. Responsibilities of Aptein. Aptein shall not, and shall cause its Affiliates not to, solicit for its own account sales of Collaboration Products. Any solicitations or requests to purchase Collaboration Products received by
Aptein or any of its Affiliates from any customer or prospective customer shall be immediately referred to Genzyme. In the event that Aptein or any of its Affiliates develops or commercializes a TGF-ß antagonist for an Ophthalmic Application
or a CAT Product, Aptein and its Affiliates shall comply with all applicable laws and regulations in connection with such activities, including but not limited to those related to “off-label” promotion of biopharmaceutical products.

  
 7.6. General and Administrative Services. General and
administrative services required for the conduct of the Program shall be provided at cost by any or all of Aptein, Genzyme or their respective Permitted Subcontractors as determined by the Steering Committee. All such costs, in addition to general
and administrative costs payable to Third Parties (such as accountants) and general and administrative costs incurred by Aptein, Genzyme or their respective Permitted Subcontractors in satisfying their respective obligations under this Agreement,
shall be considered to be Program Costs, provided that any such costs that are incurred are charged in a manner consistent with the principles set forth in Schedule 7.6. 
  
 ARTICLE 8. MANAGEMENT 
  
 8.1. Program Management Team. 
  
 8.1.1. General. The Parties have established a Program Management Team to oversee and control development of Collaboration Products. The Program
Management Team shall be composed of such number of representatives as may be appointed by the Parties from time to time. Such representatives will include individuals with expertise and responsibilities in such areas as preclinical development,
clinical development, manufacturing, regulatory affairs, marketing, sales management and reimbursement. The Parties shall be entitled, but are not obligated, to have an equal number of representatives on the Program Management Team. The Program
Management Team shall meet as needed but not less than quarterly. Genzyme and Aptein shall each designate one (1) of their respective representatives on the Program Management Team to act as Co-Chair. The Program Management Team shall appoint one of
its members to act as Secretary. Such meetings shall be at times and places or in such form (e.g., telephone or video conference) as the members of the Program Management Team shall agree. A Party may change one or more of its representatives to the
Program Management Team at any 

  

 25 

 
time. Members of the Program Management Team may be represented at any meeting by another member of the Program Management Team or by a deputy. Any approval,
determination or other action agreed to by unanimous consent of the members of the Program Management Team or their deputies present at the relevant Team meeting shall be the approval, determination or other action of the Program Management Team,
provided at least one (1) representative of each of Genzyme and Aptein is present at such meeting. Representatives of either Genzyme and Aptein or their respective Affiliates who are not members of the Program Management Team may attend meetings of
the Program Management Team as agreed to by the representative members of the other Party. The Co-Chairs of the Program Management Team may designate project leaders to the extent it deems it necessary or advisable. Each Party shall bear its own
travel costs and expenses relating to Program Management Team meetings, which costs and expenses shall not be considered Program Costs. 
  
 8.1.2. Development Program Functions. During the term of the Development Program, the Program Management Team shall coordinate, expedite and
control the development of Collaboration Products to obtain Regulatory Approvals. The Program Management Team will (a) develop and recommend to the Steering Committee updates to the Development Plans (including annual development budgets), (b)
facilitate the flow of information with respect to development work being conducted for each Collaboration Product throughout the Territory and (c) discuss and cooperate regarding the conduct of such development work. 
  
 8.1.3. Minutes. The Program Management Team shall keep accurate
minutes of its deliberations which shall record all proposed decisions and all actions recommended or taken. The Secretary shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to all members of the Program
Management Team within ten (10) business days after each meeting and shall be approved, if appropriate, at the next meeting. All records of the Program Management Team shall at all times be available to all of the Parties 
  
 8.2. Business and Commercialization Committee. 
  
 8.2.1. General. The Parties have established a Business and
Commercialization Committee in order to facilitate communication and decision-making with respect to business development, partnering and pre-commercialization activities associated with the Program and to perform such other activities as may be
agreed upon from time to time by the Steering Committee. The Business and Commercialization Committee shall be composed of such number of representatives as may be appointed by the Parties from time to time; provided that at least one (1) of each
Party’s representatives to the Business and Commercialization Committee shall also be a member of the Steering Committee. The Parties shall be entitled, but shall not be obligated, to have an equal number of representatives on the Business and
Commercialization Committee. The Business and Commercialization Committee shall appoint one (1) of its members to act as Secretary. The Business and Commercialization Committee shall meet as needed, at such times and places or in such form (such as
telephone or video conference) as the members of such Committee shall agree. A Party may change one or more of its representatives to the Business and Commercialization Committee at any time. Representatives of either Party or their respective
Affiliates who are not members of the Business and Commercialization 

  

 26 

 
Committee may attend meetings of such Committee as agreed to by the representative members of the other Party. Each Party shall bear its own travel costs and
expenses related to Business and Commercialization Committee meetings, which costs and expenses shall not be considered Program Costs. 
  
 8.2.2. Functions. The Business and Commercialization Committee shall identify, review, articulate and implement activities to facilitate the
commercial development of Collaboration Products. Such activities may include, without limitation, partnering and licensing activities and pre-commercialization planning. The Business and Commercialization Committee shall allocate day-to-day
responsibility for such activities among the Parties and/or their respective Affiliates, as appropriate, and provide regular updates to the Steering Committee of its activities. The Business and Commercialization Committee shall not be a
decision-making body; rather, all decisions regarding the Business and Commercialization Committee’s activities shall require the approval of the Steering Committee. 
  
 8.2.3. Minutes. The Business and Commercialization Committee shall keep accurate minutes of its deliberations which
shall record all proposed decisions and all actions recommended or taken. The Secretary shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to all members of the Business and Commercialization Committee within ten
(10) business days after each meeting. All records of the Business and Commercialization Committee shall at all times be available to both Genzyme and Aptein. 
  

8.2.4. Commercialization Activities. The Parties agree that the formation and operation of the Business and Commercialization Committee shall in
no way dilute the rights accruing to Genzyme hereunder with respect to the commercialization of Collaboration Products, including without limitation Genzyme’s right to retain final decision-making authority for all commercialization activities.

  
 8.3. Steering Committee. 
  
 8.3.1. General. The Parties have established a Steering Committee to
oversee and manage the collaboration contemplated by this Agreement. The Steering Committee shall be composed of three (3) representatives appointed by Genzyme and three (3) representatives appointed by Aptein. Such representatives will be senior
officers and/or managers of their respective companies or their Affiliates. Aptein’s initial representatives on the Steering Committee shall be [***]. Genzyme’s initial representatives on the Steering Committee shall be [***]. Genzyme and
Aptein shall each designate one (1) of their respective representatives on the Steering Committee to act as Co-Chair. The Steering Committee shall appoint one (1) of its members to act as Secretary. The Steering Committee will meet as needed, but
either Party may require that meetings be held quarterly. Such meetings shall be at times and places or in such form (e.g., telephone or video conference) as the members of the Steering Committee shall agree. A Party may change one or more of its
representatives to the Steering Committee at any time. Members of the Steering Committee may be represented at any meeting by another member of the Steering Committee or by a deputy. Any approval, determination or other action agreed to by unanimous
consent of the members of the Steering Committee or their deputies present at the relevant Steering Committee meeting shall be the approval, determination or other action of the 

  

 27 

 
Steering Committee, provided at least two (2) representatives of each of Genzyme and Aptein are present at such meeting. Representatives of either Genzyme
and Aptein or their respective Affiliates who are not members of the Steering Committee may attend meetings of the Steering Committee as agreed to by the representative members of the other Party. Each Party shall bear its own personnel and travel
costs and expenses relating to Steering Committee meetings, which costs and expenses shall not be considered Program Costs. 
  
 8.3.2. Functions. The Steering Committee shall perform the following functions: (a) determine the overall strategy for the Program in the manner
contemplated by this Agreement; (b) coordinate the activities of the Parties hereunder; (c) settle disputes or disagreements that are unresolved by the Program Management Team; (d) review and approve each Development Plan, including each significant
change and annual update thereto, submitted to it pursuant to Section 5.1.3 hereof; (e) oversee the Business and Commercialization Committee; (f) serve as the governing body of the Program; and (g) perform such other functions as appropriate to
further the purposes of this Agreement as determined by the Parties. 
  
 8.3.3. Minutes. The Steering Committee shall keep accurate minutes of its deliberations which shall record all proposed decisions and all actions recommended or taken. The Secretary shall be responsible for the preparation of draft
minutes. Draft minutes shall be sent to all members of the Steering Committee within ten (10) business days after each meeting. All records of the Steering Committee shall at all times be available to both Genzyme and Aptein. 
  
 8.4. General Disagreements. All disagreements within the Program
Management Team, the Business and Commercialization Committee and the Steering Committee shall be subject to the following: 
  
 (a) If any dispute relates to subject matter for which one of the Parties has primary responsibility pursuant to Section 5.1.4., the Party with such
responsibility shall be entitled to unilaterally resolve such dispute, or if such dispute relates to commercialization activities not described in Section 5.1.4 or partnering and licensing activities, Genzyme shall be entitled to unilaterally
resolve such dispute. 
  
 (b) If such dispute relates to subject
matter for which the Parties share joint responsibility pursuant to Section 5.1.4, the representatives to the Program Management Team or Steering Committee will negotiate in good faith for a period of not less than thirty (30) days to attempt to
resolve the dispute. In the case of the Program Management Team, any unresolved dispute shall be referred to the Steering Committee for good faith negotiations for an additional period of not less than thirty (30) days to attempt to resolve the
dispute. 
  
 (c) In the event that the dispute is not resolved
after the period specified in clause (b), the representatives shall promptly present the disagreement to the Chief Executive Officer of Genzyme and the President of Aptein, or a designee of such officer reasonably acceptable to the other Party.

  

 28 

 (d) Such executives shall meet or discuss in a telephone or video conference each Party’s views and
explain the basis for such dispute. 
  
 (e) If such executives
cannot resolve such disagreement within sixty (60) days after such issue has been referred to them, then such dispute shall be subject to the provisions of Section 15.6 hereof. 
  
 ARTICLE 9. INTELLECTUAL PROPERTY RIGHTS 
  
 9.1. Ownership. The Parties acknowledge that the ownership rights set forth herein are subject to the license grants
set forth in Article 3 above. 
  
 9.1.1. Ownership of
Inventions. All right, title and interest in all Inventions that are discovered, made or conceived solely by employees of Genzyme or others acting on behalf of Genzyme (“Genzyme Inventions”) shall be owned by Genzyme. All right,
title and interest in all Inventions that are discovered, made or conceived solely by employees of Aptein or others acting on behalf of Aptein (“CAT Inventions”) shall be owned by Aptein. All right, title and interest in all
Inventions that are discovered, made or conceived jointly by employees of Genzyme and Aptein or others acting on their behalf (“Joint Inventions”) shall be jointly owned by the Parties. Each of Genzyme and Aptein shall promptly
disclose to other Party the making, conception or reduction to practice of Inventions by its employees or others acting on behalf of such Party. 
  
 9.1.2. Ownership of Trademarks. Genzyme shall own all trademarks for the sale and use of Collaboration Products in the Territory (collectively, the
“Product Marks”), and all goodwill therein shall inure to the benefit of Genzyme, and all expenses thereof shall be considered Program Costs. All Product Marks shall be registered in the name of Genzyme if and when registered. In
the event that the applicable laws and regulations of any country in which the Steering Committee elects to register any Product Marks require that such trademark(s) be registered in the name of an entity other than Genzyme, or if the Steering
Committee determines that it is in the best interests of the Parties, then the Steering Committee shall select such entity and ensure that a duly authorized officer of such entity agrees in writing that such entity shall (a) grant Genzyme an
exclusive, fully-paid, royalty-free, irrevocable (during the term of this Agreement) right and license (with the right to grant sublicenses) to use such Product Marks in the Territory and (b) comply with the provisions of Article 13 hereof with
respect to the ownership and/or disposition of such Product Marks in the event the Program is terminated and provide the level of cooperation described in Section 14.1 hereof in connection therewith. Aptein hereby agrees that at no time during the
term of this Agreement shall it or any of its Affiliates challenge or assist others in challenging the Product Marks or the registration thereof or attempt to register any trademarks, marks or trade names confusingly similar to such Product Marks.

  
 9.1.3. Cooperation of Employees. Each Party represents
and agrees that all employees or others acting on its behalf (including without limitation its Permitted Subcontractors) in performing its obligations under this Agreement shall be obligated under a binding written agreement to assign to such Party,
or as such Party shall direct, all Inventions made or conceived by such employee or other person. In the case of non-employees working for 

  

 29 

 
other companies or institutions on behalf of either Party, such Party, as applicable, shall obtain licenses to the fullest extent available for all
Inventions made by such non-employees on behalf of such Party, as applicable, in accordance with the policies of said company or institution. The Parties agree to undertake to enforce such agreements (including, where appropriate, by legal action)
considering, among other things, the commercial value of such Inventions. 
  
 9.2. Filing, Prosecution and Maintenance of Patent Rights. 
  
 9.2.1. Filing, Prosecution and Maintenance. Each Party shall be responsible for the filing, prosecution and maintenance of all patent applications
and patents which make up its Patent Rights and which relate to the Program. The Steering Committee shall designate one of the Parties or one of its Affiliates as the Party responsible for the filing, prosecution, maintenance and enforcement of all
patent applications and patents which make up the Joint Patent Rights. For so long as any of the license grants set forth in Article 3 hereof remain in effect and upon request of the other Party, each Party agrees to file and prosecute patent
applications and maintain the Patent Rights for which it is responsible and which relate to the Program in all countries in the Territory selected by the Steering Committee. Each Party shall consult with and keep the other fully informed of
important issues relating to the preparation and filing (if time permits), prosecution and maintenance of such patent applications and patents, and shall furnish to the other Party copies of documents relevant to such preparation, filing,
prosecution or maintenance in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by the other Party and, to the extent possible in the reasonable exercise of its discretion, the filing
Party shall incorporate all such comments. 
  
 9.2.2. Patent
Costs. All costs incurred after the Effective Date associated with filing, prosecuting and maintaining patent applications and patents included within the Genzyme Patent Rights, the Genzyme Program Patent Rights, the CAT Patent Rights, the CAT
Program Patent Rights and the Joint Patent Rights shall be deemed Development Costs; provided, however, that if either Party or one of its Affiliates is exploiting any such Patent Rights to develop or commercialize a product other than
a Collaboration Product, then such Party shall bear [***] of such costs itself and [***] of such costs shall be deemed Development Costs. 
  
 9.3. Cooperation. Each Party shall make available to the other Party (or to the other Party’s authorized attorneys, agents or representatives)
its employees, agents or consultants to the extent necessary or appropriate to enable the appropriate Party to file, prosecute and maintain patent applications and resulting patents with respect to Inventions owned by a Party and for reasonable
periods of time sufficient for such Party to obtain the assistance it needs from such personnel. Where appropriate, each Party shall sign or cause to have signed all documents relating to said patent applications or patents at no charge to the other
Party. 
  
 9.4. Notification of Patent Term Restoration.
Each Party shall notify the other Party of (a) the issuance of each United States patent included within the Patent Rights for which the notifying Party or one of its Affiliates is responsible, giving the date of issue and patent number for each
such patent, and (b) each notice pertaining to any patent included within the Patent Rights for which the notifying Party is responsible which it receives as patent owner pursuant to 

  

 30 

 
the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, including notices pursuant to §§101 and 103 of such Act from persons who
have filed an abbreviated New Drug Application. Such notices shall be given promptly, but in any event within ten (10) business days after the issuance of such patent or receipt of each such notice pursuant to such Act. Each Party shall notify the
other Party of each filing for patent term restoration under such Act, any allegations of failure to show due diligence and all awards of patent term restoration (extensions) with respect to the Patent Rights for which the notifying Party or one of
its Affiliates is responsible. 
  
 9.5. No Other Technology
Rights. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest in or other right to the Patent Rights, Technology or Manufacturing
Know-How of the other Party, including items owned, controlled or developed by the other Party, or transferred by the other Party to said Party at any time pursuant to this Agreement. It is understood and agreed that this Agreement does not grant
either Party any license or other right in the Patent Rights or Technology of the other Party for uses other than as specified in Article 3 hereof and this Article 9. 
  
 9.6. Enforcement of Patent Rights; Defense of Infringement Actions. Each Party shall promptly notify the other in
writing of any Third Party infringement in the Field of any patents or patent applications for which it or one of its Affiliates is responsible pursuant to Section 9.2 above or if any allegation of infringement is made against either Party or any of
its Affiliates by a Third Party because of the manufacture, use or sale of a Collaboration Product or because of attempts to invalidate Patent Rights. 
  
 9.6.1. First Right to Respond. Each Party shall have the first right to respond to or defend (in consultation with the Steering Committee) against
such challenge or infringement of the Patent Rights for which it or one of its Affiliates is responsible pursuant to Section 9.2 above or charge of infringement. In the event such Party elects to so respond or defend, the other Party will cooperate
with the responding Party’s legal counsel, join in such suits as may be brought by the responding Party to enforce its Patent Rights, and be available at the responding Party’s reasonable request to be an expert witness or otherwise to
assist in such proceedings. 
  
 9.6.2. Sharing of Litigation
and Settlement Expenses. The costs incurred (a) in responding to or defending against a challenge to a Party’s Patent Rights that relate to the Program, or defending against a charge that the manufacture, use or sale of Collaboration
Products infringe the Patent Rights of Third Parties, and in assisting in connection with any of the foregoing, (b) in settling any such actions, which may not be done without the prior written consent of the Steering Committee, which consent shall
not be unreasonably be withheld or delayed, and (c) as damages paid as a result of such actions, shall be deemed Program Costs. 
  
 9.6.3. Second Right to Respond. If a responsible Party does not exercise its right to respond to or defend against challenges or infringements of
its Patent Rights as provided in Section 9.6.1 above within thirty (30) days of becoming aware of or being notified of such challenges or infringements, then the other Party shall have the option to do so at its sole cost (and the responsible Party
shall agree to be joined as a party plaintiff) following its good faith 

  

 31 

 
determination that such action is in the best interest of the Program after giving good faith consideration to the position of the responsible Party in not
so responding or defending; provided that in such case all amounts so recovered from such Third Party shall be retained by the Party undertaking such response or defense and the Party so responding shall have no further obligations to the
other Party with respect to the response or defense thereof. Notwithstanding the foregoing, the provisions of this Section 9.6.3 shall be subject to any countervailing provisions of applicable law and contractual obligations to Third Parties
existing as of the Effective Date. 
  
 9.6.4 Recovery of
Costs. If either Party recovers monetary damages from a Third Party in connection with any action described in this Section 9.6, such damages shall be applied in the following manner: (i) first, the Parties shall be reimbursed, on a pro
rata basis, for all costs and expenses incurred by them with such action; and (ii) any remaining recovery shall be shared by the Parties in proportion with their respective Percentage Interests. 
  
 ARTICLE 10. CONFIDENTIALITY 
  
 10.1. Nondisclosure Obligations. Except as otherwise provided in this
Article 10, during the term of this Agreement and for a period of five (5) years thereafter, the Parties shall, and shall cause their respective Permitted Subcontractors to, maintain in confidence and use only for purposes specifically authorized
under this Agreement (a) confidential information and data resulting from or related to the development of Collaboration Products and (b) all information and data not described in clause (a) but supplied by the other Party under this Agreement and
marked or identified as “Confidential.” 
  
 For purposes
of this Article 10, information and data described in clause (a) or (b) of the preceding paragraph shall be referred to as “Information.” To the extent it is reasonably necessary or appropriate to fulfil its obligations or exercise
its rights under this Agreement, a Party may disclose Information to its Affiliates, sublicensees, consultants, outside contractors and clinical investigators, on a need-to-know basis and on the condition that such entities or persons agree to keep
the Information confidential for the same time periods and to the same extent as such Party is required to keep the Information confidential; and a Party or its sublicensees may disclose such Information to government or other regulatory authorities
to the extent that such disclosure is reasonably necessary to obtain patents or authorizations to conduct clinical trials with and to market commercially Collaboration Products. The obligation not to disclose Information shall not apply to any part
of such Information that: (i) is or becomes patented, published or otherwise becomes publicly known other than by acts of the Party obligated not to disclose such Information or its Affiliates or sublicensees in contravention of this Agreement; (ii)
can be shown by written documents to have been disclosed to the receiving Party or its Affiliates or sublicensees by a Third Party, provided that such Information was not obtained by such Third Party directly or indirectly from the other
Party under this Agreement; (iii) prior to disclosure under this Agreement, was already in the possession of the receiving Party or its Affiliates or sublicensees, provided that such Information was not obtained directly or indirectly from
the other Party under this Agreement; (iv) can be shown by written documents to have been independently developed by the receiving Party or its Affiliates without breach of any of the provisions of this Agreement; or (v) is required to be disclosed
to comply with 
  

 32 

 
applicable laws or regulations, or with a court or administrative order, provided that the original disclosing Party receives prior written notice of
such disclosure and that the receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure. 
  
 10.2. Terms of this Agreement; Press Releases. The Parties further
agree to seek confidential treatment for the filing of this Agreement with the U.S. Securities and Exchange Commission, the London Stock Exchange, and any other applicable regulatory authority or securities exchange, and shall agree upon the content
of the request for confidential treatment made by each Party in respect of such filing. Except as permitted by the foregoing provisions or as otherwise required by law, Genzyme and Aptein each agree, and shall cause its Affiliates to agree, not to
disclose any terms or conditions of this Agreement to any Third Party without the prior consent of the other Party; provided that each Party and its Affiliates shall be entitled to disclose the terms of this Agreement without such consent to
potential investors or other financing sources on the condition that such entities or persons agree to keep such terms confidential for the same time periods and to the same extent as such Party is required to keep such terms confidential. The
Parties agree that all press releases related to the Program shall be issued jointly and that the Party preparing any such press release shall provide the other Party with a draft thereof reasonably in advance of disclosure so as to permit the other
Party to review and comment on such press release. Notwithstanding the foregoing, the Parties shall agree upon a press release to announce the execution of this Agreement, together with a corresponding backgrounder and/or question and answer outline
for use in responding to inquiries about this Agreement; thereafter, the Parties and their respective Affiliates may disclose to Third Parties (including their respective shareholders) the information contained in such press release, backgrounder
and question and answer outline without the need for further approval by the other. 
  
 10.3. Publications. Each Party recognizes the mutual interest in obtaining valid patent protection. Consequently, a Party or any of its Affiliates, or any of their respective employees or consultants, wishing
to make a publication (including any oral disclosure made without obligation of confidentiality) relating to work performed as part of the Program (the “Publishing Party”) shall transmit to the other Party (the “Reviewing
Party”) a copy of the proposed publication at least forty-five (45) days prior to submission for publication. The Reviewing Party shall have the right to (a) request a delay in publication or presentation in order to protect patentable
information, (b) propose modifications to the publication for patent reasons or (c) request that the information be maintained as a trade secret. 
  
 If the Reviewing Party requests a delay as described in clause (a) above, the Publishing Party shall delay submission or presentation of the publication
for a period of ninety (90) days to enable patent applications protecting each Party’s rights in such information to be filed. Upon the expiration of forty-five (45) days from transmission of such proposed disclosures to the Reviewing Party,
the Publishing Party shall be free to proceed with the written publication or the oral presentation, respectively, unless the Reviewing Party has requested the delay described above. 
  
 To the extent possible in the reasonable exercise of its discretion, the Publishing Party shall incorporate all
modifications proposed under clause (b) above. If a trade secret that is the 

  

 33 

 
subject of a request made under clause (c) above cannot be otherwise protected without unreasonable expense to the Reviewing Party, such information shall be
omitted from the publication. 
  
 ARTICLE 11. REPRESENTATIONS AND
WARRANTIES 
  
 11.1. Authorization. Each Party warrants and
represents to the other that (a) it has the legal right and power to enter into this Agreement, to extend the rights and licenses granted to the other in this Agreement, and to perform fully its obligations hereunder, (b) this Agreement has been
duly executed and delivered and is a valid and binding agreement of such Party, enforceable in accordance with its terms, (c) such Party has obtained all necessary approvals to the transactions contemplated hereby, (d) such Party has not made nor
will it make any commitments to others in conflict with or in derogation of such rights or this Agreement, and (e) the execution and delivery of this Agreement and the performance of such Party’s obligations hereunder will not conflict with or
breach the terms of any agreement that such Party has with any Third Party as of the Effective Date. 
  
 11.2. Intellectual Property Rights. 
  
 11.2.1. Aptein hereby represents and warrants that, as of the Effective Date, (a) it possesses an exclusive right, title and interest in or to the CAT
Patent Rights and the CAT Technology in the Field and in the Territory and a non-exclusive right, title and interest in or to the CAT Background Patent Rights, (b) that the CAT Patent Rights, the CAT Background Patent Rights and the CAT Technology
are free and clear of any lien or other encumbrance and (c) that it has the right to (i) enter into the obligations set forth in this Agreement and (ii) grant the rights and licenses set forth in Article 3 hereof. 
  
 11.2.2. Aptein hereby represents and warrants that (i) neither it nor any of
its Affiliates is aware of any valid, issued or granted patents that would be infringed or misappropriated by the manufacture, distribution and/or sale of Collaboration Products as contemplated by this Agreement; (ii) except for the Burnham License
and an agreement with Whittier Institute for Diabetes and Endocrinology regarding the Whittier Patent, neither it nor any of its Affiliates is currently negotiating, has engaged in negotiations within the ninety (90) day period preceding the
Effective Date, or has any current intention of engaging in negotiations, with Third Parties regarding licenses to intellectual property relating to TGF-ß antagonists; (iii) it has provided to Genzyme true and complete copies of all license
agreements (including all amendments thereto) existing as of the Effective Date relating to the CAT Patent Rights, CAT Background Patent Rights and CAT Technology; and (iv) Schedule 1.15 contains a complete and accurate list of all royalty
obligations existing as of the Effective Date with respect to the CAT Patent Rights and CAT Background Patent Rights. 
  
 11.2.3. Genzyme hereby represents and warrants that, as of the Effective Date, (a) it possesses a non-exclusive right, title and interest in or to the
Genzyme Patent Rights and the Genzyme Technology, (b) that the Genzyme Patent Rights and the Genzyme Technology are free and clear of any lien or other encumbrance and (c) that it has the right to (i) enter into the obligations set forth in this
Agreement and (ii) grant the rights and licenses set forth in Article 3 hereof. 
  

 34 

 11.3. Warranties. Genzyme warrants that (i) any Collaboration Products delivered by Genzyme
pursuant to Section 6.2 hereof, if any, will conform in all material respects to the Specifications, the conditions of any Regulatory Approvals regarding the manufacturing process, and any applicable requirements of the Regulatory Scheme regarding
the manufacturing process, and (ii) the Collaboration Products sold pursuant to Section 7.2 hereof will be marketed and sold in all material respects in accordance with the conditions of any applicable Regulatory Approvals and any applicable
labeling claims. 
  
 11.4. Disclaimer of Representations and
Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, AND THE NON-INFRINGEMENT OF ANY THIRD PARTY PATENTS OR PROPRIETARY RIGHTS. ALL UNIFORM COMMERCIAL CODE WARRANTIES ARE EXPRESSLY DISCLAIMED BY THE PARTIES. 
  
 11.5. Limitation of Liability. IT IS AGREED BY THE PARTIES THAT NO PARTY SHALL BE LIABLE TO ANOTHER PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE)
OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. Remedies shall be limited to claims for amounts due hereunder or as otherwise provided in this Agreement, including claims for
indemnification as provided in Section 12.1 hereof. 
  
 ARTICLE 12.
INDEMNITY 
  
 12.1. Indemnity Obligations. Each Party (the
“Indemnifying Party”) shall indemnify the other Party and its Affiliates, directors, officers, employees and agents and their respective successors, heirs and assigns (each an “Indemnified Person”) against any
liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon them arising from bodily injury or property damage claims made by Third Parties asserted against the Indemnified
Person and its Affiliates, directors, officers, employees and agents under this Agreement or arising under any theory of liability (including product liability actions in the form of tort, warranty or strict liability) concerning a Collaboration
Product or an External Product; provided that it shall be a condition to such indemnity that (a) the Indemnified Person seeking indemnification acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best
interests of the Parties, (b) the act for which indemnification is sought did not constitute gross negligence or reckless or intentional misconduct by such Indemnified Person, (c) the Indemnified Person provides the indemnifying Parties with prompt
written notice 

  

 35 

 
of any claim, suit, action, demand or judgment for which indemnification is sought hereunder, (d) the Indemnified Person cooperates fully in the defense of
such claim, suit, action or demand, and (e) payment and indemnification of any matter disposed of by a compromise payment by such Indemnified Person, pursuant to consent decree or otherwise, shall have been approved by the indemnifying Parties,
which approval shall not be unreasonably withheld or delayed, or by a court of competent jurisdiction. 
  
 12.2. Insurance. 
  
 (a) Each Party shall each maintain, or shall cause its Affiliates to maintain, at its own cost product liability and comprehensive general liability
insurance coverage in amounts reasonably determined by the Steering Committee from time to time, but in no event shall such insurance be for an amount [***]. The insurance will contain a deductible to be determined by the Steering Committee. The
aforementioned product liability and comprehensive general liability insurance shall be obtained as soon as practicable after the Effective Date, but in no event later than ninety (90) days thereafter, from an insurance carrier approved by the
Steering Committee. Genzyme shall also provide coverage under its property and transit insurance policies as approved by the Steering Committee, and the costs of the insurance premiums associated with such coverage shall be included in the Program
Costs. 
  
 (b) Each Party will furnish the other Party a
certificate(s) from an insurance carrier (having a minimum AM Best rating of A or better) showing all insurance set forth above. 
  
 (c) The certificate(s) with respect to the foregoing insurance will include statements substantially to the effect that such insurance is applicable to
all contracts between the Parties and that such insurance may be cancelled only after thirty (30) days’ written notice to the other Party. The insurance, and the certificate(s), will (a) name each of the Indemnified Parties as additional
insureds with respect to matters arising from this Agreement, (b) provide that such insurance is primary to any liability insurance carried by the other Party and (c) provide that underwriters and insurance companies of the other Party may not have
any right of subrogation against the insured Party (including their respective officers, directors, employees, servants, Affiliates, agents, successors and assigns) except in the event a claim results from a Party’s gross negligence or willful
misconduct. Such certificate(s) shall be made available to each Party upon reasonable advance request. 
  
 (d) The Steering Committee shall review the adequacy of the insurance described above on a quarterly basis and the Steering Committee shall have the power
to reasonably direct the modification of such insurance. 
  
 ARTICLE 13. TERM AND TERMINATION 
  
 13.1. Term.
Subject to earlier termination according to its provisions this Agreement shall remain in force and of effect until all of the obligations of each Party to the other have expired. 
  

 36 

 13.2. Termination of Program. The Program may be terminated in the following circumstances:

  
 13.2.1. For Certain Material Breaches. If (a) either
Aptein or Genzyme fails to use commercially reasonable and diligent efforts to perform any material duty imposed upon such Party under this Agreement or a Development Plan or a Commercialization Plan (other than those duties relating solely to the
License Rights), (b) either Genzyme or Aptein fails to make three (3) or more payments in accordance with Section 4.2 hereof, or (c) Genzyme fails to make a payment in accordance with Section 4.4, and in each case such failure to perform is not
cured within sixty (60) days of written notice thereof from the non-breaching Party, the non-breaching Party may elect, in its sole discretion, to (i) enforce the terms of this Agreement and seek any and all remedies available to it at law and in
equity, or (ii) terminate the Program on written notice to the other Party with the consequences set forth in Section 13.3.1 below. Save in the case of a breach involving a failure to make three (3) or more payments in accordance with Section 4.2
hereof or a breach by Genzyme by failing to make a payment in accordance with Section 4.4, such 60-day period shall be extended to one hundred twenty (120) days if the breaching Party has engaged in good faith efforts to remedy such default within
such 60-day period and indicated in writing to the non-breaching Party prior to the expiration of such 60-day period that it believes that it will be able to remedy the default within such 120-day period, but such extension shall apply only so long
as the breaching Party is engaging in good faith efforts to remedy such default. It is understood and agreed that the failure of a Permitted Subcontractor to perform its obligations on behalf of a Party shall not excuse the subcontracting Party from
any obligation to the other Party hereunder (except under the conditions described in Section 15.1 below), and that either Party may exercise its rights under clause (a) above upon the failure of the other Party’s Permitted Subcontractor to use
commercially reasonable and diligent efforts to perform any material duty subcontracted to such Permitted Subcontractor. 
  
 13.2.2. For Convenience. Either Genzyme or Aptein may elect to terminate the Program for any reason at any time with the consequences set forth in
Section 13.3.2 below after the earlier of (i) such time as Genzyme has received Final Marketing Approval for the first Collaboration Product or (ii) December 31, 2006 if Genzyme has not received Final Marketing Approval for the first Collaboration
Product on or before such date, upon one (1) year prior written notice to the other Party (during which one-year period the obligations of the Parties, including without limitation obligations with respect to funding Program Costs, shall continue in
full force and effect). 
  
 13.2.3. Upon Bankruptcy. Either
Genzyme or Aptein may terminate the Program with the consequences set forth in Section 13.3.3 below upon the occurrence of an Insolvency Event of the other Party. Genzyme may also terminate the Program with the consequences set forth in Section
13.3.3 below upon the occurrence of an Insolvency Event of CAT. 
  
 13.2.4. Upon a Change of Control. Either Aptein or Genzyme may elect to terminate the Program with the consequences set forth in Section 13.3.4 [***] written notice to the other Party in the event that the other Party is a party to a
transaction in which (a) any Third Party or group of related Third Parties shall directly or indirectly become the beneficial owner of capital stock representing fifty percent (50%) or more of the total voting rights of all of the 

  

 37 

 
capital stock of the other Party then outstanding or otherwise acquires the power to direct or cause the direction of the management and policies of such
Party or the power to elect or appoint more than fifty percent of the members of the Board of Directors of such Party, or (b) the other Party shall consolidate or merge with any other person and the stockholders of such Party of record immediately
prior to the consummation of such transaction do not beneficially own capital stock representing fifty percent (50%) or more of the total voting rights of the surviving corporation after the consummation of such transaction. Genzyme may also elect
to terminate the Program with the consequences set forth in Section 13.3.4 [***] written notice to Aptein in the event that CAT is a party to any of the foregoing transactions. Termination of the Program pursuant to this Section 13.2.4 shall only be
effective if the notice referred to above is delivered to non-terminating Party no later than the expiration of the committed Program funding obligation of the non-terminating Party under the Development Plan in effect as of the effective date of
such transaction, as announced by the non-terminating Party. Any termination of the Program pursuant to this Section 13.2.4 shall be effective as of the last day of the calendar quarter in which notice of termination is given to the non-terminating
Party. 
  
 13.2.5. Upon Failure to File BLA. Aptein may
elect to terminate the Program, with the consequences set forth in Section 13.3.5 below and upon one hundred eighty (180) days prior written notice to Genzyme, at any time after September 30, 2010 if Genzyme has not filed a BLA with the FDA for a
Collaboration Product on or before such date; provided, however, such date shall be conditioned upon the continuing absence of any adverse condition or event that warrants a delay in the development, clinical testing or commercialization of a
Collaboration Product including, but not limited to, any of the conditions and events described in Section 15.1 below, the inability to produce preclinical or clinical supplies, events that would cause delays in clinical studies (e.g.,
difficulties in patient recruitment, negative toxicological or pharmacological test results or an adverse clinical event), challenges within the regulatory process, or intellectual property impediments to marketing a Collaboration Product that the
Parties could not reasonably have foreseen; and provided, further, that such date shall be extended by a period equal to the pendency of any such adverse condition or event. 
  
 13.2.6. Upon Mutual Consent. The Parties may immediately terminate the Program at any time upon mutual written
consent. In the event of such a termination, the Parties shall mutually agree upon the disposition of the Patent Rights, Technology and Manufacturing Know-How relating to the Program. 
  
 13.3. Effects of Termination of the Program. 
  
 13.3.1. For Certain Material Breaches. In addition to the rights and duties set forth in Sections 13.4 and 13.5
below, Genzyme and Aptein shall have the following rights and duties upon termination of the Program pursuant to Section 13.2.1(ii) above: 
  
 (a) all licenses granted pursuant to Article 3 shall be revoked (except for the License Rights, which shall remain in full force and effect unless such
rights shall have been terminated pursuant to Section 13.6), the non-breaching Party shall obtain from the breaching Party the irrevocable right and license, with the right to grant sublicenses, under the breaching Party’s Patent Rights,
Technology and Manufacturing Know-How to develop, make, 

  

 38 

 
have made, use, offer for sale, sell, have sold, import and export Collaboration Products in the Field and in the Territory, and the breaching Party shall
execute such documents and take all action as may be necessary or desirable to affect the foregoing; provided that such license shall be for the same level of exclusivity as the rights granted with respect thereto under Section 3.1 hereof;
and provided, further, that any license granted hereunder shall be subject to the obligation of the non-breaching Party to use commercially reasonable and diligent efforts to develop and market Collaboration Products pursuant to such license;

  
 (b) any Regulatory Approvals filed, “orphan drug”
designations in the Field and clinical data owned or licensed, and any trademarks owned or licensed by the breaching Party or its Affiliates shall be (i) assigned or exclusively licensed to the non-breaching Party or any Third Party or Affiliate
designated by such Party until such time as the non-breaching Party or its designee is qualified to hold such Regulatory Approvals, “orphan drug” designations or trademarks under the applicable provisions of the Regulatory Scheme and (ii)
transferred or assigned to the non-breaching Party or its designee, as appropriate, as soon as practicable thereafter; provided, however, that in any country where such transfer or assignment is not possible, the breaching Party shall use
commercially reasonable and diligent efforts to ensure that the non-breaching Party has the benefit of such Regulatory Approvals and “orphan drug” designations and to this end consents to any regulatory authority cross-referencing to the
data and information on file with any regulatory authority as may be necessary; and 
  
 (c) the non-breaching Party shall become obligated to pay the breaching Party an amount equal to [***] of the Fair Value (as defined in Section 13.3.6 below) of the breaching Party’s interest in the Program as of
the effective date of termination, plus interest thereon at the Prime Rate of interest reported from time to time by the Chase Manhattan Bank, New York, New York, from the date of termination to the date payment is made (the “Breach Buyout
Amount”), payable as follows: 
  
 (1)
if the non-breaching Party elects to sell, license or otherwise dispose of all or any portion of the breaching Party’s (or its Affiliates’) right, title and interest in the Program, then the non-breaching Party shall, upon any such sale,
license or other disposition, pay the breaching Party an amount equal to [***] of the net proceeds of such sale, license or other disposition when such payments are actually paid; 
  
 (2) for as long as the non-breaching Party has not sold, licensed or otherwise disposed of all or a portion
of its right, title and interest in the Program which is equal to or greater than the breaching Party’s Percentage Interest as of the date of termination, the non-breaching Party shall pay the breaching Party [***] 
  
 (3) on the later to occur of: (A) the [***] of the date of
termination and (B) the [***] of the date of First Commercial Sale of a Collaboration Product, the non-breaching Party shall pay the breaching Party [***]; 
  
 provided, that the aggregate amount of all payments made under clauses (1), (2) and (3) shall not exceed the Breach Buyout Amount. 
  

 39 

 13.3.2. For Convenience. In addition to the rights and duties set forth in Sections 13.4 and 13.5
below, Genzyme and Aptein shall have the following rights and duties upon termination of the Program pursuant to Section 13.2.2 above: 
  
 (a) all licenses granted pursuant to Article 3 shall be revoked (except for the License Rights, which shall remain in full force and effect unless such
rights shall have been terminated pursuant to Section 13.6), the non-terminating Party shall have an option exercisable upon written notice to the terminating Party [***] hereof to obtain from the terminating Party the irrevocable right and license,
with the right to grant sublicenses, under the terminating Party’s Patent Rights, Technology and Manufacturing Know-How to develop, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Products in the Field and
in the Territory, and the terminating Party shall execute such documents and take all action as may be necessary or desirable to affect the foregoing; provided that such license shall be for the same level of exclusivity as the rights granted
with respect thereto under Section 3.1; and provided, further, that any license granted hereunder shall be subject to the obligation of the non-terminating Party to use commercially reasonable and diligent efforts to develop and market
Collaboration Products pursuant to such license; 
  
 (b) upon
exercise of its license option provided in paragraph (a) of this Section 13.3.2, any Regulatory Approvals filed, “orphan drug” designations in the Field and clinical data owned or licensed, and any trademarks owned or licensed the
terminating Party shall be (i) assigned or exclusively licensed to the non-terminating Party or any Third Party or Affiliate designated by such Party until such time as the non-terminating Party or its designee is qualified to hold such Regulatory
Approvals, “orphan drug” designations or trademarks under the applicable provisions of the Regulatory Scheme and (ii) transferred or assigned to the non-terminating Party or its designee, as appropriate, as soon as practicable
thereafter; provided, however, that in any country where such transfer or assignment is not possible, the breaching Party shall use commercially reasonable and diligent efforts to ensure that the non-breaching Party has the benefit of such
Regulatory Approvals and “orphan drug” designations and to this end consents to any regulatory authority cross-referencing to the data and information on file with any regulatory authority as may be necessary; 
  
 (c) upon the exercise of its license option provided in paragraph (a) of
this Section 13.3.2, the non-terminating Party shall become obligated to pay to the terminating Party an amount equal to [***] of the Fair Value (as defined in Section 13.3.6 below) of the terminating Party’s interest in the Program as of the
effective date of termination, plus interest thereon at the Prime Rate of interest reported from time to time by the Chase Manhattan Bank, New York, New York, from the date of termination to the date payment is made, payable on the terms and
conditions and in accordance with the schedule of payments set forth in Section 13.3.1(c), mutatis mutandis, except each reference to the [***] in paragraph 13.3.1(c)(3) shall instead be deemed to refer to the [***]; 
  
 (d) (i) if the license option provided in paragraph (a) of this Section
13.3.2 is not exercised, then the terminating Party shall have the option, exercisable upon written notice to the non-terminating Party within [***] of the expiration of the license option period described in Section 13.3.2(a), to obtain from the
non-terminating Party the irrevocable right and license, with 

  

 40 

 
the right to grant sublicenses, under the non-terminating Party’s Patent Rights, Technology and Manufacturing Know-How to develop, make, have made, use,
offer for sale, sell, have sold, import and export Collaboration Products in the Field and in the Territory, and the non-terminating Party shall execute such documents and take all action as may be necessary or desirable to affect the foregoing;
provided that such license shall be for the same level of exclusivity as the rights granted with respect thereto under Section 3.1; and provided, further, that any license granted hereunder shall be subject to the obligation of the
terminating Party to use commercially reasonable and diligent efforts to develop and market Collaboration Products pursuant to such license; and (ii) upon the exercise of such option, the terminating Party shall be granted the rights and become
obligated to make the payments described in Section 13.3.2(b) and (c), mutatis mutandis, except each reference to the terminating Party shall instead be deemed to refer to the non-terminating party and vice versa; and 
  
 (e) if neither Party exercises the license options provided in Sections
13.3.2(a) and (d), the Parties shall then sell all right, title and interest in the Program to the highest bidder within [***] from the date of termination and the proceeds shall be allocated between the Parties in proportion to their Percentage
Interests as of the date of termination. 
  
 13.3.3. Upon
Bankruptcy. In addition to the rights and duties set forth in Sections 13.4 and 13.5 below, Genzyme and Aptein shall have the following rights and duties upon termination of the Program pursuant to Section 13.2.3 above: 
  
 (a) all licenses granted pursuant to Article 3 shall be revoked (except for
the License Rights, which shall remain in full force and effect unless such rights shall have been terminated pursuant to Section 13.6), the terminating Party shall obtain from the non-terminating Party the irrevocable right and license, with the
right to grant sublicenses, under the non-terminating Party’s Patent Rights, Technology and Manufacturing Know-How to develop, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Products in the Field and in
the Territory, and the non-terminating Party shall execute such documents and take all action as may be necessary or desirable to affect the foregoing; provided that such license shall be for the same level of exclusivity as the rights
granted with respect thereto under Section 3.1 hereof; and provided, further, that any license granted hereunder shall be subject to the obligation of the terminating Party to use commercially reasonable and diligent efforts to develop and
market Collaboration Products pursuant to such license; 
  
 (b)
any Regulatory Approvals filed, “orphan drug” designations in the Field and clinical data owned or licensed, and any trademarks owned or licensed by the non-terminating Party or its Affiliates shall be (i) assigned or exclusively licensed
to the terminating Party or any Third Party or Affiliate designated by such Party until such time as the terminating Party or its designee is qualified to hold such Regulatory Approvals, “orphan drug” designations or trademarks under the
applicable provisions of the Regulatory Scheme and (ii) transferred or assigned to the terminating Party or its designee, as appropriate, as soon as practicable thereafter; provided, however, that in any country where such transfer or
assignment is not possible, the breaching Party shall use commercially reasonable and diligent efforts to ensure that the non-breaching Party has the benefit of such Regulatory Approvals and “orphan drug” designations and to this end
consents to any regulatory authority cross-referencing to the data and information on file with any regulatory authority as may be necessary; and 
  

 41 

 (c) the terminating Party shall become obligated to pay to the non-terminating Party an amount equal to
[***] (as defined in Section 13.3.6 below) of the non-terminating Party’s interest in the Program as of the effective date of termination, plus interest thereon at the Prime Rate of interest reported from time to time by the Chase Manhattan
Bank, New York, New York, from the date of termination to the date payment is made, payable on the terms and conditions and in accordance with the schedule of payments set forth in Section 13.3.1(c), mutatis mutandis. 
  
 13.3.4. Upon a Change of Control. In addition to the rights and duties
set forth in Sections 13.4 and 13.5 below, Genzyme and Aptein shall have the following rights and duties upon termination of the Program pursuant to Section 13.2.4 above: 
  
 (a) all licenses granted pursuant to Article 3 shall be revoked (except for the License Rights, which shall remain in full
force and effect unless such rights shall have been terminated pursuant to Section 13.6), the terminating Party shall obtain from the non-terminating Party the irrevocable right and license, with the right to grant sublicenses, under the
non-terminating Party’s Patent Rights, Technology and Manufacturing Know-How to develop, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Products in the Field and in the Territory, and the non-terminating
Party shall execute such documents and take all action as may be necessary or desirable to affect the foregoing; provided that such license shall be for the same level of exclusivity as the rights granted with respect thereto under Section
3.1; and provided, further, that any license granted hereunder shall be subject to the obligation of the terminating Party to use commercially reasonable and diligent efforts to develop and market Collaboration Products pursuant to such
license; 
  
 (b) any Regulatory Approvals filed, “orphan
drug” designations in the Field and clinical data owned or licensed, and any trademarks owned or licensed by the non-terminating Party or its Affiliates shall be (i) assigned or exclusively licensed to the terminating Party or any Third Party
or Affiliate designated by such Party until such time as the terminating Party or its designee is qualified to hold such Regulatory Approvals, “orphan drug” designations or trademarks under the applicable provisions of the Regulatory
Scheme and (ii) transferred or assigned to the terminating Party or its designee, as appropriate, as soon as practicable thereafter; provided, however, that in any country where such transfer or assignment is not possible, the breaching Party
shall use commercially reasonable and diligent efforts to ensure that the non-breaching Party has the benefit of such Regulatory Approvals and “orphan drug” designations and to this end consents to any regulatory authority
cross-referencing to the data and information on file with any regulatory authority as may be necessary; and 
  
 (c) the terminating Party shall become obligated to pay to the non-terminating Party [***]. The CoC Buyout Amount shall consist solely of the following:

  
 (1) a royalty on annual Net Sales of each
Collaboration Product [***], on an incremental basis, at the following rates (it being understood that the terminating Party shall be responsible for all Third Party royalties associated with the sale of such Collaboration Product): 
  

	 Portion of Net Sales of Collaboration
 Product in each calendar year

	  	Royalty Rate

	 Less than [***]
	  	[***]
	 Equal to or greater than [***] but less than [***]
	  	[***]
	 Equal to or greater than [***] but less than [***]
	  	[***]
	 Greater than [***]
	  	[***]

  

 42 

 The CoC Buyout Royalty, shall not, however, be payable on any Collaboration Product during the [***]
following the First Commercial Sale of such Collaboration Product; and 
  
 (2) a cash payment in an amount to be determined by the Parties in good faith and payable on the effective date of termination. If both Parties agree it is practicable they will commence good faith discussions
regarding the amount of such cash payment, prior to the completion of a transaction that would trigger a Party’s right to terminate the Program pursuant to Section 13.2.4, upon the request of the Party which would have such termination right.
In the event the Parties are unable to agree upon the amount of such cash payment within one hundred and twenty days (120) days of the effective date of termination, then such amount shall be determined by an investment banking firm selected by
mutual agreement of the Parties with such determination being based on a calculation of the difference, if any, obtained by subtracting the probabilized net present value of the CoC Buyout Royalty (calculated on the effective date of termination)
from the CoC Buyout Amount. The costs and expenses incurred in connection with such determination shall be shared equally by the Parties. 
  
 13.3.5. Upon Failure to File BLA. In addition to the rights and duties set forth in Sections 13.4 and 13.5 below, Genzyme and Aptein shall have the
following rights and duties upon termination of the Program pursuant to Section 13.2.5 above: 
  
 (a) all licenses granted pursuant to Article 3 shall be revoked (except for the License Rights, which shall remain in full force and effect unless such
rights shall have been terminated pursuant to Section 13.6), Aptein shall obtain from Genzyme a non-exclusive, irrevocable right and license, with the right to grant sublicenses, under the Genzyme Patent Rights, Genzyme Program Patent Rights,
Genzyme Technology and the Manufacturing Know-How owned or controlled by Genzyme to develop, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Products in the Field and in the Territory, and Genzyme shall execute
such documents and take all action as may be necessary or desirable to affect the foregoing; provided that any license granted hereunder shall be subject to the obligation of Aptein to use commercially reasonable and diligent efforts to
develop and market Collaboration Products pursuant to such license; 
  
 (b) any Regulatory Approvals filed, “orphan drug” designations in the Field and clinical data owned or licensed, and any trademarks owned or licensed by Genzyme or 

  

 43 

 
its Affiliates shall be (i) assigned or exclusively licensed to Aptein or any Third Party or Affiliate designated by Aptein until such time as Aptein or its
designee is qualified to hold such Regulatory Approvals, “orphan drug” designations or trademarks under the applicable provisions of the Regulatory Scheme and (ii) transferred or assigned to Aptein or its designee, as appropriate, as soon
as practicable thereafter; provided, however, that in any country where such transfer or assignment is not possible, Genzyme shall use commercially reasonable and diligent efforts to ensure that Aptein has the benefit of such Regulatory
Approvals and “orphan drug” designations and to this end consents to any regulatory authority cross-referencing to the data and information on file with any regulatory authority as may be necessary; and 
  
 (c) Aptein shall become obligated to pay to Genzyme an amount equal to [***]
(as defined in Section 13.3.6 below) of Genzyme’s interest in the Program as of the effective date of termination, plus interest thereon at the Prime Rate of interest reported from time to time by the Chase Manhattan Bank, New York, New York,
from the date of termination to the date payment is made, payable on the terms and conditions and in accordance with the schedule of payments set forth in Section 13.3.1(c), mutatis mutandis. 
  
 13.3.6. Fair Value. For purposes of this Section 13.3, the
“Fair Value” of a Party’s interest in the Program shall be the amount an informed and willing buyer under no compulsion to buy would be willing to pay such Party on the basis that it is an informed and willing seller under no
compulsion to sell for such Party’s right, title and interest in the Program as set out in this Agreement determined as of the date of termination, which determination shall be made by the mutual agreement of Genzyme and Aptein. In the event
that Genzyme and Aptein are unable to agree upon the Fair Value within [***] of the date of termination, the Fair Value shall be determined by an investment banking firm selected by mutual agreement of Genzyme and Aptein, and the costs and expenses
incurred in connection with the engagement of such investment banking firm shall be shared equally by Genzyme and Aptein. 
  
 13.4. Inventory. Upon the termination of this Agreement, if Aptein obtains a license pursuant to Section 13.3, Aptein shall have the option to
purchase Genzyme’s inventory of Collaboration Products (not already paid for by the Parties) as of the date of termination. Within ten (10) days after such termination, Aptein shall elect in writing to either (a) permit Genzyme to sell off its
remaining inventory of Collaboration Products, provided that Genzyme shall comply with all of the terms and conditions of this Agreement restricting such selling activities as in effect immediately prior to such termination, or (b) purchase
Genzyme’s inventory of Collaboration Products. If Aptein fails to make such an election, Genzyme shall be permitted to sell-off its remaining inventory of Collaboration Products in accordance with clause (a) of this Section 13.4. Any purchase
of Genzyme’s inventory of Collaboration Products shall be at the price as stated in the then-current price list, less a handling charge to be reasonably determined by the Parties in good faith. 
  
 13.5. Cooperation. If either Genzyme or Aptein (the “Assuming
Party”) shall assume the Program rights from the other Party (the “Responsible Party”) in accordance with the provisions of Article 13 hereof, the Responsible Party shall promptly provide to the Assuming Party (or any Third
Party or Affiliate designated by the Assuming Party) all Technology, Manufacturing Know-How and access to regulatory filings sufficient to allow the Assuming 

  

 44 

 
Party to perform the duties assumed. The Responsible Party shall further use its best efforts to provide all assistance required by the Assuming Party with
respect to such transfer so as to permit the Assuming Party to begin to perform such duties as soon as possible to minimize any disruption in the continuity of supply or marketing of Collaboration Products. In addition, if upon the date this
Agreement is terminated Collaboration Products are being manufactured in facilities owned or leased by the Responsible Party, the Responsible Party agrees to lease such facilities to the Assuming Party on commercially reasonable terms for a period
of up to [***]. 
  
 13.6. Termination of License Rights.
The License Rights may be terminated in the following circumstances, and upon the effective date of any such termination Genzyme’s right to practice under the License Rights shall cease: 
  
 13.6.1. For Convenience. Genzyme may terminate the License Rights at
any time upon [***] notice to Aptein. 
  
 13.6.2. For Material
Breach. Aptein may terminate the License Rights in the event Genzyme shall have materially breached or defaulted in the performance of any of its material obligations hereunder relating to the License Rights, including without limitation the
failure to make when due a payment required under Sections 4.5 or 4.6, and such default is not cured within [***] after written notice thereof was received by Genzyme from Aptein. Any termination shall become effective at the end of such [***]
period unless Genzyme (or any other party on its behalf) shall have cured any such breach or default prior to the expiration of the [***]. 
  
 13.6.3 For Insolvency. Aptein may terminate the License Rights upon the occurrence of an Insolvency Event of Genzyme. 
  
 13.7. Survival of Rights and Duties. No termination of the Program,
the License Rights or this Agreement shall eliminate any rights or duties of the Parties accrued prior to such termination. The provisions of Articles 1, 10 and 12 and Sections 2.3, 3.2, 4.3, 4.4, 4.6.5, 4.10, 4.12, 9.1.1, 9.1.3, 9.3, 9.5, 11.4,
11.5, 13.3, 13.4, 13.5, 13.6, 13.7, 15.4, 15.5, 15.6, and 15.7, hereof shall survive any termination of this Agreement. 
  
 ARTICLE 14. TAX PROVISIONS 
  
 14.1. Purpose. The Parties have determined that the Program will likely be deemed to create a partnership for U.S. tax purposes. The sole purpose
of this Article 14 is to define the rights and obligations of the Parties in order to enable them to comply with their reporting obligations as partners in such deemed partnership for U.S. federal, state and/or other domestic or foreign income tax
purposes. The Parties do not intend hereby to form a partnership or joint venture for any purpose, and neither Party shall be a partner for any purpose other than the filing of tax returns in any jurisdictions in which the operation of the Program
requires partnership tax returns to be filed. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior consent of the
other Party to do so. 
  

 45 

 14.2. Capital Accounts. A separate account (a “Capital Account”) shall be
maintained for each Party and adjusted in accordance with U.S. Treasury Regulations Section 1.704-1(b). Without limitation of the foregoing: 
  
 (a) The Capital Account of each Party shall be increased by the cash and/or property that each Party has agreed to contribute to the Program pursuant to
Sections 3.1 and 4.1. The cash and agreed value of any property contributed by each Party as of the Effective Date is as follows: 
  

	 	Genzyme:	[***] 

	 	Aptein:	[***] 

  
 (b) The Capital Account of each Party shall be decreased by the amounts distributed to the Party in accordance with Section 4.4 or treated as distributed to such Party under Section 14.5 below. 
  
 14.3. Allocations. Except as provided in Section 14.4 below, items of
Program income, gain, loss or deductions for each taxable year shall be allocated to the Parties and debited or credited to their Capital Accounts as follows: 
  

(a) Costs or expenses shall be allocated to each Party according to its obligations to pay or contribute to the payment of such cost or expense.

  
 (b) Depreciation shall be allocated to each Party according to
its obligations to contribute to the adjusted tax basis of the underlying asset, and depreciation recapture shall reflect each Party’s share of depreciation. 
  
 (c) Net income shall be allocated to the Parties in proportion to their Percentage Interests. 
  
 (d) Gain or loss from the sale, exchange, distribution or other disposition
of a depreciable asset shall be allocated to each Party according to its obligation to contribute to the adjusted tax basis of the underlying asset. Gain or loss from the sale, exchange, distribution or other disposition of all other assets shall be
allocated to the Parties in proportion to their Percentage Interests. 
  
 14.4. Compliance with the Code. All of the provisions of this Article 14 relating to the maintenance of Capital Accounts are intended to comply with Treasury Regulations promulgated under Section 704(b) of the U.S. Internal Revenue
Code of 1986, as amended (the “Code”) and shall be interpreted and applied in a manner consistent with such Treasury Regulations. The minimum gain chargeback provisions of Treasury Regulations Section 1.704-2(f), partner nonrecourse
debt minimum gain provisions of Treasury Regulations Section 1.704-2(i)(4), and the qualified income offset provision of Treasury Regulations Section 1.704-2(b)(2) shall be considered to be part of this Article 14. If any Party contributes
appreciated or depreciated property, allocations to the Parties shall be adjusted as required by Section 704(c) of the Code to take into account the built-in gain or loss at the time of such contribution. If there are any nonrecourse deductions, as
defined in Treasury Regulations Section 1.704-2(i)(2), such deductions shall be allocated to the Party who bears the economic risk of loss for the nonrecourse liability to which the deductions are attributable. 
  

 46 

 14.5. Withholding. All amounts required to be withheld from undistributed income pursuant
to Code Sections 1441, 1445 and 1446 or any other provision of federal, state, local or foreign tax law shall be treated as amounts actually distributed to the affected Party for all purposes under this Agreement. 
  
 14.6. Termination. Upon termination of the Program, the deemed
tax partnership, the terms of which are set forth in this Article 14, shall be deemed to have been liquidated for tax purposes and its assets distributed tot he Parties as follows: 
  
 (a) All cash representing unexpended capital contributions shall be returned to the Party contributing such cash.

  
 (b) The fair market value of all partnership property shall be
determined and the gain or loss for such property allocated in accordance with the provisions of Sections 14.3 and 14.4 above. 
  
 (c) If a party has a negative Capital Account, it shall be required to contribute an amount of cash necessary to achieve a Capital Account equal to
U.S.$0. 
  
 (d) Next, proceeds from the deemed liquidation shall
be distributed to the Parties having positive Capital Accounts, pro rata, in accordance with their relative positive Capital Accounts (after giving effect to all contributions, distributions and allocations for all periods) until all such
positive Capital Accounts are reduced to U.S.$0. 
  
 (e)
Thereafter, proceeds shall be distributed to the Parties in accordance with their respective Percentage Interests. 
  
 14.7. Tax Matters Partner. Genzyme shall be designated as the tax matters partner, as defined in Section 6231(a)(7) of the Code, for
purposes of this Article 14 and as such shall take all actions permitted to be taken by a tax matters partner under the Code. All costs incurred by the Tax Matters Partner in performing such duties shall be Program Costs. The Tax Matters Partner
shall cause all income and other required U.S. federal, state and/or other domestic or foreign tax returns contemplated by this Article 14 to be prepared and to be timely filed with the appropriate authorities and, in connection therewith, shall
make such elections and other determinations for U.S. federal, state and/or other domestic or foreign tax purposes as it deems appropriate, including, without limitation, elections of methods of depreciation and elections to adjust the basis of
property pursuant to Sections 754, 734(b), and 743(b) of the Code, or comparable provisions of state, local or foreign law. Notwithstanding the foregoing, Genzyme shall provide Aptein with a copy of all tax returns filed hereunder and, if Aptein
disagrees with any elections or other determinations made in such returns, the Parties shall discuss such disagreements in good faith. If, following good faith discussions, the Parties are unable to reach agreement as to any elections or other
determinations made in tax returns, such disagreement shall be referred to an Expert’s Decision. 
  

 47 

 ARTICLE 15. MISCELLANEOUS 
  
 15.1. Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including
without limitation, fire, floods, embargoes, war, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority or the other Party; provided, however, that the Party so affected shall use commercially reasonable and diligent efforts to avoid or remove such causes of non-performance, and shall continue performance hereunder with
reasonable dispatch wherever such causes are removed. Each Party shall provide the other Parties with prompt written notice of any delay or failure to perform that occurs by reason of forcemajeure. The Parties shall mutually seek a
resolution of the delay or the failure to perform in good faith. 
  
 15.2. Assignment. Subject to Article 13 above, this Agreement may not be assigned or otherwise transferred by any Party without the consent of the other Party; provided, however, that either Party may, without such consent,
assign its rights and obligations under this Agreement (a) in connection with a corporate reorganization, to any member of an affiliated group, all or substantially all of the equity interest of which is owned and controlled by such Party or its
direct or indirect parent corporation or (b) in connection with a merger, consolidation or sale of substantially all of such Party’s assets to an unrelated Third Party; and provided, further, that such Party’s rights and obligations
under this Agreement shall be assumed by its successor in interest in any such transaction and shall not be transferred separate from all or substantially all of its other business assets, including without limitation those business assets that are
the subject of this Agreement. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 15.2 shall be void. 
  
 15.3. Severability. Each Party hereby agrees that it does not intend
to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this
Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it can be
reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity
of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions.

  
 15.4. Notices. Any consent, notice or report required
or permitted to be given or made under this Agreement by one of the Parties hereto to the other shall be in writing, delivered personally or by facsimile (and promptly confirmed by personal delivery or courier), by a next 

  

 48 

 
business day delivery service of a nationally recognized overnight courier service or by courier, postage prepaid (where applicable), addressed to such other
Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor in accordance with this Section 15.4 and shall be effective upon receipt by the addressee. 
  

	 If to Genzyme:
	  	Genzyme Corporation
	 	  	One Kendall Square, 1400 Building
	 	  	Cambridge, Massachusetts 02139-1562, U.S.A.
	 	  	Attention: Executive Vice President, Therapeutics
	 	  	Facsimile: +1-617-374-7333
		
	 with a copy to:
	  	            Genzyme Corporation
	 	  	One Kendall Square, 1400 Building
	 	  	Cambridge, Massachusetts 02139-1562, U.S.A.
	 	  	Attention: Chief Legal Officer
	 	  	Facsimile: +1-617-252-7553
		
	 If to Aptein:
	  	                        Aptein, Inc.
	 	  	2711 Centerville Road, Suite 400
	 	  	Wilmington, Delaware 19808, U.S.A.
		
	 with a copy to:
	  	Cambridge Antibody Technology Limited
	 	  	Milstein Building
	 	  	Granta Park
	 	  	Cambridge CB1 6GH, England
	 	  	Attention: Company Secretary
	 	  	Facsimile: +44-1223-471472

  
 15.5. Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, U.S.A. without regard to any choice of law principle that would dictate the application of the laws of another jurisdiction. 

 
 15.6. Dispute Resolution. Any disputes arising between the Parties
relating to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement (a
“Dispute”), which has not resolved in accordance with the provisions of Section 8.4 hereof, shall be referred to an Expert’s Decision. If the parties fail to reach agreement in respect of any dispute within sixty (60) days of
an expert being appointed in accordance with Schedule 1.23 then such dispute may finally be resolved by binding arbitration as herein provided. Except as otherwise provided in this Section 15.6, any arbitration hereunder shall be conducted by
the International Chamber of Commerce. Each such arbitration shall be conducted in the English language by a panel of three (3) arbitrators (the “Arbitration Panel”). Each of Aptein and Genzyme shall appoint one (1) arbitrator to
the Arbitration Panel and the third arbitrator shall be appointed by the two (2) arbitrators appointed by Aptein and Genzyme. The Arbitration Panel shall apply the then-current International Chamber of Commerce Arbitration Rules for the resolution
of any dispute submitted to arbitration. Any such arbitration 

  

 49 

 
shall be held in Paris, France. The Arbitration Panel shall have the authority to grant specific performance, and to allocate between the Parties the costs
of arbitration in such equitable manner as it shall determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of
enforcement, as the case may be. 
  
 15.7. Injunctive
Relief. The Parties hereby acknowledge that a breach of their respective obligations under Article 10 hereof may cause irreparable harm and that the remedy or remedies at law for any such breach may be inadequate. The Parties hereby agree that,
in the event of any such breach, in addition to all other available remedies hereunder, the non-breaching Party shall have the right to obtain equitable relief to enforce Article 10 hereof. 
  
 15.8. Entire Agreement. This Agreement (and the schedules hereto)
contains the entire understanding of the Parties and their respective Affiliates with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and
made a part of this Agreement, including, but not limited to, the Confidential Disclosure Agreement between Genzyme and CAT dated May 19, 1999, as amended. This Agreement may be amended, or any term hereof modified, only by a written instrument duly
executed by the Parties hereto. Each of the Parties hereby acknowledges that this Agreement is the result of mutual negotiation and therefore any ambiguity in its terms shall not be construed against the drafting Party. 
  
 15.9. Headings. The captions to the several Articles and Sections
hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 
  
 15.10. Waiver. Except as expressly provided herein, the waiver by either Party hereto of any right hereunder or of any failure to perform or any
breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other failure to perform or breach by said other Party, whether of a similar nature or otherwise, nor shall any singular or partial exercise of such right
preclude any further exercise thereof or the exercise of any other such right. 
  
 15.11. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 [remainder of page intentionally left blank] 
  

 50 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

  

	 GENZYME CORPORATION

		
	 By:
	 	 /s/

	 Title:
	 	  

	 Date:
	 	  

  

	 OPTEIN INC.

		
	 By:
	 	 /s/

	 Title:
	 	  

	 Date:
	 	  

 SCHEDULE 1.7 
  
 CAT BACKGROUND PATENT RIGHTS 
  

	1.	“Single Domain Ligands, Receptors Comprising said Ligands, Methods for their Production and Use of Said Ligands and Receptors” PCT/GB89/01344, filed November 13, 1989.

  

	2.	“Co-expression of Heteromeric Receptors” PCT/US90/02890, filed May 16, 1990. 

  

	3.	“Method for Isolating Receptors Having a Preselected Specificity” PCT/US90/02835, filed May 16, 1990. 

  

	4.	“A new method for tapping the immunological repertoire” PCT/US90/02836, filed May 16, 1990. 

  

	5.	“Cell-free Synthesis and Isolation of Novel Genes and Polypeptides” PCT/US90/06582, filed October 4, 1990. 

  

	6.	“Methods for producing members of specific binding pairs” PCT/GB91/01134, filed July 10, 1991. 

  

	7.	“Methods for producing members of specific binding pairs” PCT/GB92/00883, filed May 15, 1992. 

  

	8.	“Treatment of Cell Populations” PCT/GB92/01483, filed August 10, 1992. 

  

	9.	“Production of chimeric antibodies – a combinational approach” PCT/GB92/01755, filed September 23, 1992. 

  

	10.	“Production of anti-self antibodies from antibody segment repertoires and displayed on phage” PCT/GB92/02240, filed December 2, 1992. 

  

	11.	“Methods for producing members of specific binding pairs” PCT/GB93/00605, filed March 24, 1993. 

  

	12.	“SBP members with a chemical moiety covalently bound within the binding site; production and selection thereof” PCT/GB94/01422, filed June 30, 1994.

  

	13.	“Retargeting antibodies” PCT/GB94/02019, filed September 16, 1994. 

  

	14.	“Recombinant Binding Proteins and peptides” PCT/GB02662, filed December 5, 1994. 

  

	15.	“Labelling and selection of Specified Binding Molecules” PCT/GB97/01834, filed July 8, 1997. 

 SCHEDULE 1.8 
  
 CAT PATENT RIGHTS 
  

	1.	[***] 

  

	2.	[***] 

  

	3.	[***] 

  

	4.	[***] 

  

	5.	[***] 

  

	6.	“Inhibiting transforming growth factor to prevent accumulation of extracellular matrix” Border & Ruoslahti; PCT/US90/05566 filed September 27, 1990.

  

	7.	“Inhibiting TGF-beta to Prevent Accumulation of Extracellular Matrix” Border & Ruoslahti; PCT/US92/10550 filed December 4, 1992. 

  

	8.	[***] 

  

	9.	“Specific binding members for human transforming growth factor beta: materials and methods” Thompson et al; PCT/GB96/02450 filed October 7, 1996. 

 

	10.	[***] 

  

	11.	“Specific binding members for TGFß1” Thompson et al; PCT/GB00/01679 filed May 2, 2000. 

  

	12.	US patent 5,958,411 “Methods of inhibiting ECM accumulation in the CNS by inhibition of TGFß” Logan & Baird, issued September 28, 1999. 

 SCHEDULE 1.15 
  
 THIRD PARTY ROYALTIES 
  

	1.	License Agreement dated January 7, 1997 between CAT and MRC, with certain royalty rates, as may be amended from time to time, which shall include all royalty payments due to The
Scripps Research Institute and Stratagene pursuant to an agreement dated 25 June 1999. 

  

	2.	Therapeutic Antibodies Agreement, dated December 31, 1997 between CAT and Dyax Corp., with a royalty rate of [***], as such agreement may be amended from time to time.

  

	3.	Diagnostic Antibodies Agreement dated December 31, 1997 between CAT and Dyax Corp., with a royalty rate of [***], as such agreement may be amended from time to time.

  

	4.	The Burnham License, as such agreement may be amended from time to time, with royalty rates of: 

  

	 	•	[***] on Net Sales of Licensed Products payable to Burnham; 

  

	 	•	[***] on Net Sales of Licensed Products payable to Integra; and 

  

	 	•	[***] payable to Burnham on sales of a product, whether an antibody-based or non-antibody-based antagonist, which would infringe a Valid Claim in the Dasch Patents, but not infringe
a Valid Claim in the Licensed Patent Rights 

  
 Capitalized terms used above are as defined in the Burnham License. 
  

	5.	[***] 

 SCHEDULE 1.23 
  
 EXPERT’S DECISION 
  

	1.	Any matter or dispute to be determined by an expert under this Agreement (“Expert”) shall be referred to a person suitably qualified to determine that matter or dispute
who shall be nominated jointly by the parties or, failing agreement between the Parties within twenty (20) business days of a written request by either Party to the other seeking to initiate the Experts Decision procedure, either Party may (1) in
the case of disputes relating to any financial aspect of this Agreement request the President for the time being of the American Institute of Certified Public Accountants or any successor body to it to nominate the Expert or (2) in the case of all
other disputes request the President for the time being of the Biotechnology Industry Organization or any successor body to it to nominate the Expert. 

  

	2.	The Parties shall within fourteen (14) days of the appointment of the Expert (or such longer period as may be mutually agreed upon by the Parties) meet with him or her in order to
agree to a program for the exchange of any relevant information and the structure to be adopted for the negotiations. 

  

	3.	In all cases the terms of appointment of the Expert by whomsoever appointed shall include: 

  

	 	3.1	a commitment by the Parties to share equally the Expert’s fee; 

  

	 	3.2	a requirement on the Expert to act fairly as between the Parties and according to the principles of natural justice; 

  

	 	3.3	a requirement on the Expert to hold professional indemnity insurance both then and for three years following the date of his or her determination: 

  

	 	3.4	a commitment by each Party to supply to the Expert in confidence (even as to the other Party) all such assistance, documents and information as he or she may require for the purpose
of his or her determination. 

  

	 	3.5	a commitment by the Parties that all negotiations connected with the dispute shall be conducted in confidence and without prejudice to the rights of the Parties in any further
proceedings. 

  

	4.	If the Parties accept the Expert’s recommendations or otherwise reach agreement on the resolution of the dispute, such agreement shall be reduced to writing and, once it is
signed by their duly authorize representatives, shall be binding on the Parties (save in the case of negligence or manifest error). 

  

	5.	Failing agreement, either of the Parties may invite the Expert to provide a non-binding but informative opinion in writing. 

 SCHEDULE 1.31 
  
 GENZYME PATENT RIGHTS 
  
 U.S. patent 5,571,714, entitled “Monoclonal Antibodies Which Bind Both Transforming Growth Factors ß1 and ß2 and Methods of Use.” 
  
 U.S. patent 5,772,998, entitled “Monoclonal Antibodies to Transforming Growth
Factor-Beta and Methods of Use.” 
  
 U.S. patent 5,783,185, entitled
“Monoclonal Antibodies to Transforming Growth Factor-Beta and Methods of Use.” 
  
 U.S. patent 6,090,383, entitled “Monoclonal Antibodies to Transforming Growth Factor-Beta and Methods of Use.” 
  
 [***] 
  
 [***] 
  
 U.S. Patent No. 4,774,322, entitled “Substantially Pure
TGF-ß2 Polypeptide” 
  
 Australian Patent No. 592,951, corresponding to
U.S. Patent No. 4,774,322. 
  
 Canadian Patent No. 1,261,549, corresponding to
U.S. Patent No. 4,774,322. 
  
 European Patent No. 0 169 016 B1, corresponding to
U.S. Patent No. 4,774,322. 
  
 Japanese Patent No. 2,074,953, corresponding to
U.S. Patent No. 4,774,322. 

 SCHEDULE 1.47 
  
 PERCENTAGE INTEREST 
  
 The Parties’ respective Percentage Interests shall be calculated from time to time in accordance with the following formulae; provided,
however, that the Parties’ respective Percentage Interests on the Profitability Date shall be fixed at such level for the remaining term of the Program, subject to adjustment from time to time following the Profitability Date should Genzyme
fund operating losses allocable to Aptein as a result of the operation of the last clause of the penultimate sentence of Section 4.1: 
  
 Aptein’s Percentage Interest
            =            [***] 
  
 where 
  

	[***]	

  
 Genzyme’s Percentage Interest         =             [***] 
  
 For purposes of this Schedule 1.47, a “Pivotal Trial” of a Collaboration Product shall mean a human clinical trial
of a Collaboration Product designed to be of a size and statistical significance to support an BLA or MAA filing alone, or in combination with other studies. If it is unclear whether or not a study design will be sufficient to support an BLA or MAA
filing (other than by virtue of the uncertainty of efficacy data from that trial), the study will be deemed to be a Pivotal Trial on the initiation of activities to support an BLA or MAA filing. Initiation of a Phase III clinical trial will be
deemed to be initiation of a Pivotal Trial. 
  
 If, as a result of
the application of the foregoing formulae, Aptein’s Percentage Interest is less than [***], Aptein’s Percentage Interest shall be deemed to be [***]. Further, upon the earlier to occur of: (i) the Profitability Date and (ii) the effective
date of termination of the Program, Aptein’s Percentage Interest is [***] as a result of the application of the foregoing formulae, [***]. 
  
 An example of the application of the foregoing formulae follows: 
  

[***] 

 SCHEDULE 4.6.1 
  
 CALCULATION OF ROYALTIES ON 
 NET SALES OF GENZYME PRODUCTS 
  
 [***]

 SCHEDULE 5.1.3 
  
 DEVELOPMENT PLAN 
  
 [***] 

 SCHEDULE 7.6 
  
 GENERAL AND ADMINISTRATIVE EXPENSES 
  
 General and Administrative costs shall be regarded as Program Costs to the extent that they are either Direct Supporting
G&A Costs or Attributable Supporting G&A Costs. 
  
 Direct
and Attributable Supporting G&A Costs are, respectively, those necessarily incurred in undertaking Direct and Attributable Supporting G&A Activities and will comprise an appropriate proportion of the Relevant External Costs and Relevant
Internal Costs incurred in providing the resource. 
  
 Each Direct
or Attributable Supporting G&A Activity will have a Cost Driving Factor which will be used to measure the extent to which G&A resources are utilised and so determine the proportion of costs to be included. 
  
 Directly Supporting G&A Activities are discrete activities undertaken
from time to time: 
  
 EITHER specifically
in supporting the provision of research, development and commercialisation resources for the execution of the Development Plan and which would not otherwise be undertaken. 
  
 OR Necessarily in the administration or furtherance of the affairs of the Collaboration (but not in
respect of the affairs of the Parties as individuals). 
  
 Attributable Supporting G&A Activities are those undertaken continuously over a period of time to provide infrastructure and services to directly support the activities of the Program out of a pool of resources shared with the remainder
of the activities of the Parties. 
  
 For either type of
Supporting G&A Activity there must be a distinct and direct relationship between the activity concerned and benefits received by the collaboration. 
  
 What is and is not a Direct or Attributable Supporting G&A activity and the applicable Cost Driving Factor will be determined by the Program
Management Team 
  
 The following table contains examples of
Direct and Supporting G&A Activities. It is not exhaustive, not binding and for illustrative purposes only: 
  

	 Activity

	  	 Example

	  	 Potential Cost Driver

	 Directly Supporting
 G&A Activities
	  	Dealing with the recruitment of individuals necessary for the conduct of the Development Plan	  	Time taken
			
	 	  	Development of software and procedures specifically for use in the collaboration.	  	Time taken
			
	 	  	Dealing with collaboration tax matters	  	Time taken (or Relevant External Cost)
			
	 	  	Project management	  	Time taken
			
	 	  	Accounting services (specific collaboration transaction processing and costing activities)	  	Time taken
			
	 	  	Public or investor relations (issue of joint press releases etc.)	  	Time taken (or Relevant External Cost)
			
	 	  	Legal services (drawing up contracts with collaboration sub-contractors etc.)	  	Time taken (or Relevant External Cost)
			
	 Attributable supporting G&A Activities
	  	IT support services	  	Per head involved in the collaboration
			
	 	  	General accounting (processing payroll, T&E claims etc. of staff directly involved in the Program)	  	Per head involved in the collaboration or per transaction
			
	 	  	Procurement / Purchasing (of supplies directly consumed)	  	Per transaction
			
	 	  	Facility space, security, general maintenance	  	Per head

 Relevant External Costs are costs incurred in having an activity undertaken by a third party in an
arms-length transaction. This will generally comprise invoiced value, net of value added tax. 
  
 Relevant Internal Costs are the costs of providing the resource to undertake an activity using staff internal to the Parties. The costs will include those for staff directly engaged in providing the resource and will
comprise: 
  

	 	•	Salary, employer payroll taxes, pension contributions and other benefits 

  

	 	•	Training, travel and subsistence and consumables (stationery, refreshments etc.) 

  

	 	•	Cost of providing facilities occupied / utilised (rent, rates, premises depreciation, heat and light, telecommunications, equipment rentals and / or depreciation)

  
 Costs will be charged based on the above policy,
Relevant Internal Costs will not include any apportionment of services benefiting individual corporate parties (such as Board of Directors/CEOs office).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]